 HYDROGEL CONTACT LENS
专利摘要:
The "hydrogel contact lens" of the present invention relates to polymeric compositions used in the manufacture of biocompatible medical devices. more particularly, the present invention relates to certain monoethylenically unsaturated polymerizable group-containing polycarbosiloxane monomers capable of polymerization to form polymer compositions with desirable physical characteristics used in the manufacture of ophthalmic devices. 公开号:BR112012000503B1 申请号:R112012000503-0 申请日:2010-07-08 公开日:2019-08-20 发明作者:Alok Kumar Awasthi；Jason K. Stanbro；Jay F. Kunzler；Jeffrey G. Linhardt 申请人:Bausch & Lomb Incorporated； IPC主号:
专利说明:
“HYDROGEL CONTACT LENS” PRIORITY CLAIMS FOR PREVIOUS APPLICATIONS [0001] This patent application is partly a continuation of the US patent application. Ser. No. 12 / 499,854 filed on July 9, 2009, the contents of which are incorporated herein by reference. FIELD OF THE INVENTION [0002] The present invention relates to novel monomers used in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain monomers based on polycarbosiloxane monomers containing monoethylenically unsaturated polymerizable group capable of polymerization to form polymeric compositions with desirable physical characteristics used in the manufacture of ophthalmic devices. Such features include low modulus of elasticity, better lubricity and better hydrolytic stability. BACKGROUND OF THE INVENTION AND SUMMARY [0003] Several articles, including biomedical devices, are formed from materials containing organosilicon. A class of organosilicon-containing materials used for biomedical devices, such as soft contact lenses, are hydrogel materials containing silicone. A hydrogel is a hydrated cross-linked polymeric system that contains water in a steady state. Hydrogel contact lenses offer relatively high oxygen permeability, as well as desirable biocompatibility and comfort. The inclusion of a silicone-containing material in the hydrogel formulation generally provides higher oxygen permeability, since silicone-based materials have higher oxygen permeability than water. [0004] Organosilicon-containing materials used for biomedical devices, including contact lenses, are disclosed in the following US patents: US patent No. 4,208,506 (Deichert et al.), US patent No. 4,686,267 (Ellis et al.) , US patent No. 5,034,461 (Lai et al.) and US patent No. 5,070,215 (Bambury et al.). [0005] U.S. Patent Nos. 5,358,995 and 5,387,632 describe hydrogels Petition 870190055152, of 06/14/2019, p. 6/123 2/62 produced from various combinations of silicone macromers, TRIS, n-vinyl pyrrolidone (NVP) and DMA. The replacement of a substantial portion of the silicone macromer with TRIS reduced the modulus of the resulting hydrogels. Two publications by the same author, The Role of Bulky Polisiloxanylalkyl Methacrylates in PolyurethanePolysiloxane Hidrogels, J. Appl. Poly. Sci. Vol. 60, 1193-1199 (1996), and The Role of Bulky Polisiloxanylalkyl Methacrylates in Oxigen-Permeable Hydrogel Materials, J. Appl. Poly. Sci., Vol. 56, 317-324 (1995) also describe experimental results indicating that the module of hydrogels produced from the reaction mixtures of silicone macromers and hydrophilic monomers such as DMA decreases with the addition of TRIS. The addition of methacryloxypropyltris (trimethylsiloxy) silane (TRIS) reduced the modulus of such hydrogels, but in many instances, the modulus was even greater than could be desired. [0006] U.S. Patent No. 4,208,506 describes monomeric polyparafinsiloxanes capped with activated unsaturated groups and polymers and copolymers thereof. The monomers of U.S. Patent No. 4,208,506 are crosslinkers. However, there is still a need in the unprecedented monomer technique to provide silicone hydrogels that are soft enough to produce soft contact lenses, which have high oxygen permeability, adequate water content, and sufficient elasticity, and are comfortable for the user contact lens. BRIEF DESCRIPTION OF THE DRAWINGS [0007] None. DETAILED DESCRIPTION [0008] Unless otherwise clearly established all materials used to form a monomer mixture are listed as a percentage by weight. Also, unless otherwise clearly stated, it should be understood that all quantities of materials used to manufacture the monomers and mixtures of monomers disclosed here represent the statistical average of a normal distribution of values by weight, as are ordinarily found in the laboratory or commercial manufacture of the monomers and monomer mixtures disclosed here. Therefore, unless otherwise clearly stated, all Petition 870190055152, of 06/14/2019, p. 7/123 3/62 numerical values should be understood as modified by the term about. [0009] As used herein the terms polycarbosiloxane monomer or EDS refer to monomers with at least one group - [silyl-alkyl-siloxanyl]. The group - [silyl-alkyl-siloxanyl] - can be substituted on any atom capable of having a substituent group and the group - [silyl-alkyl siloxanyl] - can be a repeating group. The alkyl portion of the group - [silyl-alkyl-siloxanyl] - is a linking group between the silyl and siloxanyl group and is preferably 2-7 carbon atoms in length. [0010] The term monomer used here refers to compounds of varying molecular weight (i.e., typically with numerical average molecular weights of about 300 to about 100,000) that can be polymerized, and to compounds or polymers of average molecular weight high, sometimes referred to as macromonomers (that is, typically with numerical average molecular weights greater than 600) containing functional groups capable of further polymerization. Thus, it is understood that the terms organosilicon-containing monomers, silicone-containing monomers and hydrophilic monomers include monomers, macromonomers and prepolymers. Prepolymers are monomers or partially polymerized monomers that are capable of further polymerization. [0011] An organosilicon-containing monomer contains at least one [siloxanil] or at least one [silyl-alkyl-siloxanil] repeat unit, in a monomer, macromer or prepolymer. Preferably, the total Si and the attached O are present in the organosilicon-containing monomer in an amount greater than 5 percent by weight, and more preferably greater than 30 percent by weight of the total molecular weight of the organosilicon-containing monomer. A silicone-containing monomer is one that contains at least one repeating unit of [siloxanil], in a monomer, macromer or prepolymer. [0012] In a first aspect, the invention concerns monomers of formula (I): Petition 870190055152, of 06/14/2019, p. 8/123 4/62 X-L R 4 Re n (h [0013] where X is the residue of a ring opening or capping agent; L is the same or different and is a linker or bond; V is an ethylenically unsaturated polymerizable group; Ri, R2 , R3, R4, Rs, R6 are independently H, alkyl, halo alkyl, heteroalkyl, alkyl cycle, heterocycle alkyl, alkenyl, halo alkenyl, or aromatic; R7 and Rs when present are independently H or alkyl in which at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100. [0014] Ring opening agents are well known in the literature. Non-limiting examples of anionic ring-opening agents include alkyl lithiums, alkoxides, trialkylsiloxylithium, where the alkyl group may or may not contain halo atoms. [0015] Capping agents are well known in the literature. Non-limiting examples of capping agents include 3-methacryloxypropyl dimethylchlorosilane, 3acryloxypropyl dimethylchlorosilane, chlorodimethylsilane and bromodimethylsilane. Linking groups can be any divalent radical or fraction and include substituted or unsubstituted alkyl, alkyl ether, alkenyl, alkenyl ethers, halo alkyl, substituted or unsubstituted siloxanes, and monomers capable of propagating the ring opening. [0017] Ethylene-unsaturated polymerizable groups are well known to those skilled in the art. Non-limiting examples of ethylenically unsaturated polymerizable groups would include acrylates, methacrylates, vinyl carbonates, O-vinyl carbamates, N-vinyl carbamates, acrylamides and methacrylamides. [0018] Additional preferred embodiments of the monomers of the invention herein would include monomers of formula (II): Petition 870190055152, of 06/14/2019, p. 9/123 5/62 [ΙΠ [0019] where L is the same or different and is a linking group or a bond; V is an ethylenically unsaturated polymerizable group; R1, R2, R3, R4, Rs, R6 and R9 are independently H, alkyl, alkyl halo, alkyl cycle, alkyl heterocycle, alkenyl, alkenyl halo, or aromatic; R7 and Rs when present are independently H or alkyl where at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100. [0020] Additional preferred embodiments of the monomers of the invention herein would include monomers of the following formulas III and IV: [0021] wherein R9, R10 and Rn are independently H, alkyl, haloalkyl or other substituted alkyl groups; n is as previously defined and n 'is 0-10; and, [0022] where n is 1-100, preferably n is 2-80, more preferably n is 3-20, most preferably n is 5-15. [0023] Additional preferred embodiments of the monomers of the invention herein would include monomers of the following formulas V - IX: [0024] (M1-EDS6-TMS) [0025] (M1-EDS7-TMS) Petition 870190055152, of 06/14/2019, p. 12/103 6/62 (Vlk [0026] (M1-EDS9-TMS) [0027] (MIN-ED5I2-TMS) (vm. Ό (IX). (Viiih and (MI-EDS 15-TMS) Ah O [0028] L -'is Additional preferred embodiments of the monomers of the invention herein would include monomers of the following formulas X - XII: (Xlk Petition 870190055152, of 06/14/2019, p. 12/113 7/62 fXU) [0029] where R9, R10 and Rn are independently H, alkyl, haloalkyl or other substituted alkyl groups and n and n 'are as previously defined. [0030] Additional preferred embodiments of the monomers of the invention would include monomers of the following formulas XIII - XV: {Xíllk Η - * 9 here [0031] where n is as previously defined and X- is a counterion to provide a total neutral charge. [0032] Counterions capable of providing a full neutral charge are well known to those skilled in the art and would include, for example, halide and borate ions. [0033] An additional preferred embodiment of the monomers of the invention here would include the monomer of the following formula XVI: [0034] (M1-EDS7-D 3 7-TMS) Petition 870190055152, of 06/14/2019, p. 12/123 8/62 [0035] (XVÍl Formula monomers can be prepared by several synthetic methods, for example: Petition 870190055152, of 06/14/2019, p. 12/13 9/62 [0036] Monomers of formula II can be prepared by various synthetic methods, for example, as shown in example 6. [0037] In yet another aspect, the invention includes articles formed from mixtures of device-forming monomers comprising, alone or in combination, any of the monomers of formulas I - XVI. According to preferred embodiments, the article is the polymerization product of a mixture comprising at least one of the aforementioned monomers of formulas I XVI and at least a second copolymerizable monomer. The invention is applicable to a wide variety of polymeric materials, both rigid and soft ophthalmic materials, for implantation into or over an eye. Polymeric materials Petition 870190055152, of 06/14/2019, p. 12/143 Especially preferred 10/62 are ophthalmic lenses including contact lenses, phakic and aphakic intraocular lenses and horny implants, although all polymeric materials including biomaterials are contemplated within the scope of this invention. Preferred items are optically clear and used as a contact lens. [0038] The monomer blend of the present invention also provides medical devices such as artificial heart valves, buttons for lens turning, films, surgical devices, vessel substitutes, intrauterine devices, membranes, diaphragms, surgical implants, artificial blood vessels, ureters artificial tissues, artificial breast tissue and membranes intended to come into contact with body fluid outside the body, for example, membranes for kidney and heart / lung dialysis machines and the like, catheters, mouth guards, denture coatings, ophthalmic devices and, especially, hydrogel contact lenses. [0039] As presented above, unless otherwise clearly stated, it should be understood that all quantities of materials used to manufacture the monomers and monomer mixtures disclosed here represent the statistical average of a normal distribution of values by weight, such as are commonly found in the laboratory or commercial manufacture of the monomers and mixtures of monomers disclosed here. Therefore, unless otherwise clearly stated, it should be understood that all numerical values are modified by the term about. [0040] The concentration used of the polycarbosiloxane monomers containing the monoethylenically unsaturated polymerizable group of the invention here would be 0.1 to 30 weight percent of the monomer mixture. Most preferred concentrations are 0.1 to 20 weight percent. Even more preferred concentrations would be 5 to 15 weight percent. [0041] Preferred compositions of the monomer mixture have both hydrophilic and hydrophobic monomers. Depending on the specific application, used articles made from these materials may require additional hydrophobic monomers (other than the monoethylenically unsaturated polymerizable group in question containing Petition 870190055152, of 06/14/2019, p. 12/153 11/62 polycarbossiloxane monomers), possibly monomers containing silicone. Such additional silicone-containing hydrophobic monomers will be present between 0.1 to 75.8 weight percent, more preferably between 2 to 20 weight percent, even more preferably between 5 to 13 weight percent. Amounts of hydrophobic monomers containing non-silicone will be 0 to 60 percent by weight. Examples of non-silicone hydrophobic materials include alkyl acrylates and methacrylates. Especially preferred are hydrogel forming materials containing silicone. [0042] Depending on the application, used articles may also require massive monomers such as those disclosed in US patent number 6,921,802 which include methacryloxypropyl tris (trimethylsiloxy) silane (TRIS), pentamethyldisiloxanyl methyl methacrylate, tris (trimethylsilyloxy) methacryloxy, propyl phenyltretramethyl-disloxanylethyl, methyldi (trimethylsiloxy) methacryloxy methyl silane, 3- [tris (trimethylsiloxy) silyl] propyl vinyl, 3 [tris (trimethylsilyloxy) silyl] propyl allyl, and 3- [tris (trimethylsilyl)] ethyl carbide ] propyl vinyl. These massive monomers, when present, can be present in 0 to 41.2 weight percent, 34 to 41 weight percent or 25 to 41 weight percent. [0043] Organosilicon-containing hydrogels are prepared by polymerizing a mixture containing at least one organosilicon-containing monomer and at least one hydrophilic monomer. In addition, a silicone-containing monomer that functions as a crosslinking agent (a crosslinker defined as a monomer with multiple polymerizable functionalities) or a separate crosslinker can be employed. Hydrophobic crosslinkers would include methacrylates such as ethylene glycol dimethacrylate (EGDMA) and allyl methacrylate (AMA). Methacrylamide crosslinkers such as Ma2D37 allow the incorporation of greater amounts of hydrophilic comonomers in the monomer mixture than their methacrylate counterparts. This greater amount of hydrophilic comonomers provides a finished lens with a higher water content and better wettability. Crosslinker amounts would be between 0 to 76 weight percent, 2 to 20 weight percent or 5 to 13 weight percent. [0044] Polycarbosiloxane monomers containing polymerizable group Petition 870190055152, of 06/14/2019, p. 12/163 12/62 monoethylenically unsaturated of the invention here can be copolymerized with a wide variety of hydrophilic monomers to produce silicone hydrogel lenses. Suitable hydrophilic monomers include: unsaturated carboxylic acids, such as methacrylic and acrylic acids; acrylic substituted alcohols, such as 2-hydroxyethyl methacrylate and 2-hydroxyethyl acrylate; vinyl lactams, such as Nvinylpyrrolidone (NVP) and 1-vinylazonan-2-a; and acylamides, such as methacrylamide and N, N-dimethylacylamide (DMA). These hydrophilic monomers will be present, separately or in combined weight in amounts between 0 to 60 percent by weight, between 20 to 45 percent by weight, between 0 to 48.6 percent by weight, between 0 to 30 percent by weight, between 0 to 25 weight percent, 0 to 9.5 weight percent or 2 to 7 weight percent. [0045] Other examples of mixtures of silicone monomers that can be used with this invention include the following: mixtures of vinyl carbonate and vinyl carbamate monomers in the manner disclosed in U.S. Patent Nos. 5,070,215 and 5,610,252 (Bambury et al); mixtures of fluorsilicon monomers as disclosed in U.S. Patent Nos. 5,321,108; 5,387,662 and 5,539,016 (Kunzler et al.); mixtures of fumarate monomers as disclosed in U.S. Patent Nos. 5,374,662; 5,420,324 and 5,496,871 (Lai et al.) And mixtures of urethane monomers as disclosed in U.S. Patent Nos. 5,451,651; 5,648,515; 5,639,908 and 5,594,085 (Lai et al.), All of which are attributed to the same applicant, here Bausch & Lomb Incorporated, and the full disclosures are incorporated here by reference. Other suitable hydrophilic monomers will be apparent to those skilled in the art. [0046] An organic diluent can be included in the initial monomer mixture. As used herein, the terms organic diluent encompass organic compounds that minimize component incompatibility in the initial monomeric mixture and are substantially non-reactive with the components in the initial mixture. Additionally, the organic diluent serves to minimize phase separation of polymerized products produced by polymerization of the monomeric mixture. Also, the organic thinner in general will be relatively non-flammable. Petition 870190055152, of 06/14/2019, p. 12/173 13/62 [0047] Organic diluents contemplated include alcohols such as tert-butanol (TBA), tert-amyl alcohol, hexanol and nonanol; diols, such as ethylene glycol; and polyols, such as glycerol. Preferably, the organic diluent is sufficiently soluble in the extraction solvent to facilitate its removal from a cured article during the extraction step. Other suitable organic thinners will be apparent to those skilled in the art. [0048] The organic diluent is included in an effective amount to provide the desired effect (for example, minimum phase separation of polymerized products). In general, the diluent is included in 0 to 60% by weight of the monomeric mixture, with 1 to 40% by weight being more preferred, 2 to 30% by weight being even more preferred and 3 to 25% by weight being especially preferred. [0049] According to the present process, the monomeric mixture, comprising at least one hydrophilic monomer, at least one polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group and optionally the organic diluent, is modeled and cured by conventional methods such as static leakage or rotating leak. [0050] Lens formation can be by polymerization of free radicals using initiators such as azobisisobutyronitrile (AIBN) and peroxide catalysts under conditions such as those disclosed in U.S. Patent No. 3,808,179, incorporated herein by reference. Polymerization photoinitiation of the monomer mixture using initiators such as IRGACURE 819 (bis (2,4,6-trimethylbenzoyl) phenylphosphineoxide) and DAROCURE 1173 (2-hydroxy-2-methyl-1-phenyl-propan-1-a) is also well known in the art and can be used in the process of forming an article in the manner disclosed here. By careful selection of the appropriate wavelength of light to conduct photo polymerization of the monomer mixture, a finished product with desirable properties such as surface hydrophilicity and surface lubricity can result. Other important reaction conditions for light curing would include incident light intensity, time of exposure to light and controlled atmosphere, which can also be critical to providing a successful commercial product. The appropriate light intensity will depend on the conditions of Petition 870190055152, of 06/14/2019, p. 12/183 14/62 polymerization such as mold material, monomer mixture and initiator concentration ratio. For example, suitable intensities would range from 1.0 mW / cm 2 to 25.0 mW / cm 2 . Similarly, the time of exposure to light can vary, depending on the polymerization conditions. Therefore, the time of exposure to light can vary from one minute to 60 minutes. The control of atmospheric conditions to polymerize contact lenses is well known in the art. Dyes and the like can be added prior to the polymerization of the monomer. [0051] Subsequently, a sufficient amount of unreacted monomer and, when present, organic diluent, is removed from the cured article to improve the biocompatibility of the article. The release of unpolymerized monomers into the eye by installing a lens can cause irritation and other problems. Therefore, once the biomaterials formed from the mixture of polymerized monomers containing the monomers disclosed here are formed, they are then extracted to prepare them for packaging and eventual use. Extraction is carried out by exposing the polymerized materials to various solvents such as water, 2-propanol, etc. for varying periods of time. For example, an extraction process is to immerse the polymerized materials in water for about three minutes, remove the water and then immerse the polymerized materials in another aliquot of water for about three minutes, remove this aliquot of water and then sterilize the material polymerized in water, buffer solution or other packaging solution. [0052] The structure and composition of the surface determine many of the physical properties and main uses of solid materials. Characteristics such as wetness, friction and adhesion or lubricity are greatly influenced by the characteristics of the surface. The change in surface characteristics is of particular significance in biotechnical applications where biocompatibility is of particular concern. It should be remembered that, in coating medical devices, the term surface should not be limited, meaning at least a complete surface. Surface coverage must not be exact or complete to be effective for surface functionality or surface treatment. Thus, it is desired to provide a hydrogel contact lens containing organosilicon with a film of Petition 870190055152, of 06/14/2019, p. 12/193 15/62 optically clear hydrophilic surface, which will not only exhibit better wettability, but which will generally allow the use of a hydrogel contact lens containing organosilicon in the human eye for an extended period of time. In the case of a hydrogel lens containing organosilicon for prolonged use, it may be additionally desirable to provide a better hydrogel contact lens containing organosilicon with an optically clear surface film that will not only exhibit better lipid and microbial behavior, but that will generally allow the use of a hydrogel contact lens containing organosilicon in the human eye for an extended period of time. A lens with a surface treated like this would be comfortable for real use and would allow prolonged use of the lens without irritation or other adverse effects on the cornea. [0053] It may also be desirable to apply these surface enhancement coatings to implantable medical devices such as intraocular lens materials to reduce attachment of the lens epithelial cells to the implanted device and reduce friction as the intraocular lens passes through an eye inserter. Therefore, if necessary to produce a successful commercial product, the polymerized materials can optionally be coated. [0054] Contact lens coating methods and various types of contact lens coatings are well known to those skilled in the art. Methods of coating the substrate include coating by immersing the substrate in a solution containing the surface coating material. The solution containing the surface coating material can substantially contain the solvent surface coating material, or it can contain other materials such as cleaning and extraction materials. Other methods may include spray coating the device with surface coating material. In certain embodiments, it may be necessary to use suitable catalysts, for example, a condensation catalyst. Alternatively, the substrate and the other surface coating material can be subjected to autoclave conditions. In certain embodiments, the substrate and the surface coating material can be autoclaved on the packaging material that will contain the coated substrate. Once the interaction Petition 870190055152, of 06/14/2019, p. 12/20 16/62 between the substrate and the surface coating material has occurred, the remaining surface modifying agent could be substantially removed and packaging solution added to the substrate packaging material. Sealing steps and other processing steps then continue in the usual way. Alternatively, the surface modifying agent could be retained in the substrate packaging material during storage and transportation of the substrate device to the end user. [0055] Coatings for medical devices are typically oligomeric or polymeric and sized to provide properties suitable for the surface of the medical device to be coated. Coatings according to certain embodiments of the invention here will typically contain hydrophilic domain (s) which have good surface properties when the coating is associated with the substrate (i.e., the uncoated medical device). The hydrophilic domain (s) will comprise at least one hydrophilic monomer, such as, HEMA, glyceryl methacrylate, methacrylic acid (MAA), acrylic acid (AA), methacrylamide, acylamide, N, N'-dimethylmetacylamide, or N, N'-dimethylacylamide; its copolymers; hydrophilic prepolymers, such as poly (alkylene oxide) are ethylenically unsaturated, cyclic lactams such as N-vinyl-2-pyrrolidone (NVP), or derivatives thereof. Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers. Hydrophilic monomers can be non-ionic monomers, such as 2-hydroxyethyl methacrylate (HEMA), 2-hydroxyethyl acrylate (HEA), 2- (2-ethoxyethoxy) ethyl (meth) acrylate, (glyceryl acrylate), poly ( ethylene glycol (meth) acrylate), tetrahydrofurfuryl (meth) acrylate, (meth) acylamide, N, N'dimethylmethacrylamide, N, N'-dimethylacrylamide (DMA), N-vinyl-2-pyrrolidone (or other Nvinyl lactams), N-vinyl acetamide, and combinations thereof. Still further examples of hydrophilic monomers are the vinyl carbonate and vinyl carbamate monomers disclosed in U.S. Patent 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent 4,910,277. The contents of these patents are incorporated here by reference. The hydrophilic monomer can also be an anionic monomer, such as 2-methacryloyloxyethylsulfonate salts. Monomers Petition 870190055152, of 06/14/2019, p. 12/21 17/62 anionic hydrophilic substitutes, such as from acrylic and methacrylic acid, can also be used in which the substituted group can be removed by an easy chemical process. Non-limiting examples of such substituted anionic hydrophilic monomers include trimethylsilyl esters of (meth) acrylic acid, which are hydrolyzed to regenerate an anionic carboxyl group. The hydrophilic monomer can also be a cationic monomer selected from the group consisting of 3-methacrylamidopropyl-N, N, N-trimethylammonium salts, 2-methacryloyloxyethyl-N, N, Ntrimethylammonium salts, and amine-containing monomers methacrylamidopropyl-N, Ndimethyl amine. Other suitable hydrophilic monomers will be apparent to those skilled in the art. [0056] Generally, a packaging system for storing an ophthalmic lens according to the present invention includes at least one sealed container containing one or more unused ophthalmic lenses immersed in an aqueous lens packaging solution. Preferably, the sealed container is a hermetically sealed blister pack, in which a concave well containing a contact lens is covered by a sheet of metal or plastic adapted for detachment in order to open the blister pack. The sealed container can be any generally suitable inert packaging material that provides a reasonable degree of protection for the lens, preferably a plastic material, such as polyalkylene, PVC, polyamide and the like. [0057] Substrates containing organosilicon are generally hydrophobic. To improve the patient's experience, especially with regard to comfort, it is not uncommon to use a packaging solution or other method to reduce the hydrophobic character of the substrate or to provide a ready-to-use product with better lubricity. The relative hydrophobic character of a surface can be measured by many means known to those skilled in the art. An example of a method of measuring contact angle is the Sessile Drop technique. For substrates containing organosilicon a high angle of contact of sessile drop is some indication of a relatively hydrophobic material (in the dry state). Based on empirical observations, packaging solutions that provide material with an angle of Petition 870190055152, of 06/14/2019, p. 12/22 18/62 sessile drop contact less than about 75 degrees are relatively hydrophilic and tend to slide easily around a hydrophobic surface, such as that provided by a polystyrene Petri disc, when a force such as applied by a manual scalpel is used to slide the material (in this case a molded contact lens). Other packaging materials that provide a material with a contact drop angle greater than about 75 degrees are relatively hydrophobic and tend to adhere to a hydrophobic surface such as that provided by a polystyrene Petri dish. It was surprisingly found that when an organosilicon hydrogel material is packaged with a borate buffered polyphosphocholine solution, the lens behaves as if it had been packaged with a solution providing more hydrophobic packaging material (eg drop contact angle sessile greater than about 75 degrees) still behaves as slippery as a material packaged with a packaging solution that provides a material with a contact drop angle less than about 75 degrees. Therefore, a medical device packaged with a borate buffered polyphosphocholine solution is a preferred embodiment of the invention here. [0058] Selection of the appropriate packaging solution material will depend on a particular lens formulation and is therefore somewhat broad in nature. The following are non-limiting examples of representative polymers or cationic, anionic and zwitterionic components, along with nonionic surfactants and peptide-based materials that are used in packaging solutions (depending on the intended use). ANIONIC POLYMERS poly (acrylic) acid poly (acylamide-co-acrylic acid) o Carboxymethylcellulose Cationic Polymers o JR Polymer o Latent amine polymers Zwiterionic components Petition 870190055152, of 06/14/2019, p. 12/23 19/62 o Phosphocholine o Latent amino acids Polypeptides o poly (glutamic acid) o Poli (lysine) Nonionic surfactants o Tetronic T1107 o Tetronic T908 o Hydroxypropyl methylcellulose o Silicone surfactants (NVP-co-TRIS VC) o Glycereth Cocoate [0059] For the sake of simplicity, the following discussion of packaging solutions will focus on polymer conditioning agents non-ionic. It is perceived that in general the selection of a suitable packaging solution for the ophthalmic device formed from a mixture of polymerized monomers containing monomers based on polycarbosiloxane monomers containing monoethylenically unsaturated polymerizable group is within the competence of those skilled in the art. However, as noted earlier, certain packaging solutions used with an organosilicon containing device can be inventive in their own right. [0060] Any suitable nonionic polymeric conditioning agent component can be employed in accordance with the present invention, as long as it works as described here and has no substantial detrimental effect on the contact lens being stored or the lens wearer contact. This component is ophthalmically acceptable at the concentrations used. Particularly, components used are those, which are soluble in water, for example, soluble in the concentrations used in the current liquid aqueous media used. [0061] These compounds condition the lens providing one or more of the following attributes: higher viscosity for longer retention time on the lens; better wetting of the lens surface; less friction of the surface (that is, better Petition 870190055152, of 06/14/2019, p. 12/24 Lubricity); or greater comfort of a contact lens by forming a damping film on the lens surface. [0062] A class of nonionic polymeric conditioning agents includes nonionic polysaccharide. Representative examples of components suitable for use here include, but are not limited to, methyl cellulose; hydroxyethylcellulose; hydroxypropylcellulose; hydroxypropylmethylcellulose; and methylhydroxyethyl starches. [0063] Another class of nonionic polymeric conditioning agents includes polyvinylalcohols and polyvinylpyrrolidones. [0064] Another class of nonionic polymeric conditioning agents includes PEO polymers, including dPEO homopolymers, and PEO and PPO block copolymers. This class includes poloxamers and poloxamines, including those disclosed in U S patent No. 6,440,366. [0065] The previous classes of nonionic polymeric conditioning agents are for illustrative purposes only and are not intended to limit the scope of the present invention. Such polymers are known to those skilled in the art. [0066] Generally, the average molecular weight of nonionic polymeric conditioning agent is a minimum of about 1 kDa and a maximum of about 700 kDa, more preferably, about 5 kDa to 500 kDa. [0067] The amount of nonionic polymeric conditioning agent employed is that amount effective to improve the surface properties of the ophthalmic device when combined with a nonionic non-polymeric polyol. Preferably the nonionic polymeric conditioning agent is present in the packaging solution of the invention in an amount of at least 0.01% by weight / volume. The specific amount of such a component used can vary widely depending on numerous factors, for example, the specific polymeric component and nonionic polyol being employed. Generally, the concentration of the nonionic polymeric conditioning agent is from about 0.01 to about 10% by weight / weight and preferably from about 0.5 to about 1.5% by weight / weight. [0068] In one embodiment, the non-ionic non-polymeric polyol for use here, can be a non-ionic polyol containing 2 to about 12 carbon atoms and Petition 870190055152, of 06/14/2019, p. 12/25 21/62 preferably 2 to 4 carbon atoms and 2 to 8 hydroxyl groups. Representative examples of such nonionic polyols include glycerin, ethylene glycol, propylene glycol, sorbitol, mannitol, monosaccharides, disaccharides such as trehalose, and the like and mixtures thereof. In one embodiment, the nonionic polyol can be glycerin, ethylene glycol, sorbitol, mannitol, monosaccharides and mixtures thereof. [0069] The amount of non-ionic non-polymeric polyol in the packaging solution will generally be an amount sufficient to form a more uniform coating on the surface of the lens when packaged in a packaging solution according to the present invention. In general, the concentration of the non-ionic polyol will ordinarily vary from about 0.01 to about 10% by weight / weight and preferably from about 0.1 to about 3.0% by weight / weight. [0070] The packaging solutions according to the present invention are physiologically compatible. Specifically, the solution must be ophthalmically safe for use with a lens such as a contact lens, meaning that a contact lens treated with the solution is generally suitable and safe for direct placement in the eye without washing, that is, the solution is safe and comfortable for daily contact with the eye through a contact lens that has been wetted with the solution. An ophthalmically safe solution has a tonicity and pH that are compatible with the eye and includes materials, and amounts thereof, that are non-cytotoxic according to ISO standards and U.S. Food & Drug Administration (FDA) regulations. The solution could be sterile in that the absence of microbial contaminants in the product before release, must be statistically demonstrated to the degree necessary for such products. The liquid media used in the present invention are selected to have no substantial detrimental effect on the lens being treated or cared for and to allow or even facilitate the present lens treatment or treatments. The liquid media are preferably aqueous based. A particularly used aqueous liquid medium is that derived from saline, for example, a conventional saline solution or a conventional buffered saline solution. [0071] The pH of the present solutions can be maintained in the range of about 6.0 to Petition 870190055152, of 06/14/2019, p. 12/26 22/62 about 8, and preferably about 6.5 to about 7.8. Suitable buffers can be added, such as: phosphate; borate; citrate; carbonate; tris (hydroxymethyl) aminomethane (TRIS); bis (2-hydroxyethyl) -imino-tris (hydroxymethyl) amino alcohol (bis-tris); zwitterionic buffers such as N- [2-Hydroxy-1,1-bis (hydroxymethyl) ethyl] glycine (tricine) and N- [2-Hydroxy-1,1-bis (hydroxymethyl) ethyl] glycine, MOPS; N- (carbamoylmethyl) taurine (ACES); amino acids and amino acid derivatives; and their mixtures. Generally, buffers will be used in amounts ranging from about 0.05 to about 2.5 weight percent, and preferably from about 0.1 to about 1.5 weight percent of the solution. The packaging solutions of this invention preferably contain a borate buffer, containing one or more of boric acid, sodium borate, potassium tetraborate, potassium metaborate or mixtures thereof. [0072] If necessary, the solutions of the present invention can be adjusted with tonicity agents, to approximate the osmotic pressure of normal tear fluids, which is equivalent to a 0.9 percent sodium chloride solution or 2-glycerol solution, 5 percent. The solutions are made substantially isotonic with physiological saline used alone or in combination, otherwise if simply mixed with sterile water and made hypotonic or made hypertonic the lenses will lose their desirable optical parameters. Correspondingly, too much saline can result in the formation of a hypertonic solution, which will cause burning, and irritation in the eye. [0073] Examples of suitable tonicity adjusting agents include, but are not limited to, sodium and potassium chloride, dextrose, calcium and magnesium chloride and the like and mixtures thereof. Such agents are typically used individually in amounts ranging from about 0.01 to about 2.5% by weight / volume and preferably from about 0.2 to about 1.5% by weight / volume. Preferably, the tonicity agent will be employed in an amount to provide a final osmotic value of at least about 200 mOsm / kg, preferably from about 200 to about 450 mOsm / kg, more preferably from about 250 to about 400 mOsm / kg, and above all preferably from about 280 to about 370 mOsm / kg. Petition 870190055152, of 06/14/2019, p. 12/27 23/62 [0074] If desired, one or more additional components can be included in the packaging solution. Such additional component or components are chosen to confer or provide at least one beneficial or desired property for the packaging solution. Such additional components can be selected from components that are conventionally used in one or more ophthalmic device care compositions. Examples of such additional components include cleaning agents, wetting agents, nutrient agents, sequestering agents, viscosity builders, contact lens conditioning agents, antioxidants, and the like and mixtures thereof. These additional components can each be included in the packaging solutions in an effective amount to confer or provide the beneficial or desired property for the packaging solutions. For example, such additional components can be included in packaging solutions in quantities similar to the quantities of such components used in others, for example, conventional contact lens care products. [0075] The sequestering agents used include, but are not limited to, ethylene diamine disodium tetra acetate, alkali metal hexametaphosphate, citric acid, sodium citrate and the like and mixtures thereof. [0076] Antioxidants used include, but are not limited to, sodium metabisulfate, sodium thiosulfate, N-acetylcysteine, butylated hydroxyanisol, butylated hydroxytoluene and the like and mixtures thereof. [0077] The method of packaging and storing an ophthalmic lens according to the present invention includes at least packaging the ophthalmic lens immersed in the aqueous contact lens packaging solution described above. The method may include immersing the ophthalmic lens in an aqueous contact lens solution before dispensing to the customer / user directly after the contact lens is manufactured. Alternatively, packaging and storage in the solution of the present invention may occur at an intermediate point before to distribute to the end customer (user) but, after manufacturing and transporting the lens in a dry state, in which the dry lens is hydrated by immersing the lens in the packaging solution for Petition 870190055152, of 06/14/2019, p. 12/28 Contact Accordingly, a package to distribute to a customer may include a sealed container containing one or more unused contact lenses immersed in an aqueous contact lens packaging solution according to the present invention. [0078] In one embodiment, the steps leading to the present ophthalmic device packaging system include (1) molding an ophthalmic device into a mold comprising at least a first and second mold portion, (2) removing the lens from the portions of the mold, (3) introducing the packaging solution of this invention and the ophthalmic lens into the container, and (4) sealing the container. Preferably, the method also includes the step of sterilizing the contents of the container. Sterilization can take place before, or more conveniently after sealing the container and can be carried out by any suitable method known in the art, for example, by means of balanced autoclaving of the sealed container at temperatures of about 120 ° C or more. Preferred packaging is plastic bubble packaging, including a recess for receiving a contact lens and the packaging solution, where the recess is sealed with plastic caps before sterilizing the contents of the package. Especially preferred packaging would include packaging and assembly of the disposable contact lens packaging. A single package comprises a flange with a well formed in it to hold a contact lens in solution. A flexible cover plate extends over the flange and is sealed around the perimeter of the well to seal the lens and solution in the well. The cover plate can be easily detached from the flange by a user to access the lens held on it. The first and second support structures are formed opposite each other and generally extend perpendicularly to the flange. The support structures are configured to stably support the packaging on a flat surface such as a table. [0079] Each support structure includes a main wall and a secondary wall arranged in parallel planes generally spaced from each other, although the main and secondary walls may interconnect or touch along one or more points of these. In a preferred embodiment, the secondary wall is Petition 870190055152, of 06/14/2019, p. 12/29 25/62 located inwardly on a respective main wall. [0080] An assembly of the package is also disclosed, including a second package configured substantially equal to a first package, in which the first and second packages can be removably attached to each other, with the first and second support structures of each in fitting married to each other. [0081] In certain embodiments, after the extraction of unreacted monomers and any organic diluent, the modeled article, for example, an RGP lens, is optionally machined by various processes known in the art. The machining step includes cutting around a lens surface, cutting around a lens edge, polishing a lens edge, or polishing a lens edge or surface. The present process is particularly advantageous for processes in which a lens surface is cut around a lathe, since machining a lens surface is especially difficult when the surface is sticky or rubberized. [0082] Generally, such machining processes are carried out before the article is released from a part of the mold. After the machining operation, the lens can be released from the mold part and hydrated. Alternatively, the article can be machined after removing the mold part and then hydrated. [0083] The following examples are provided to allow those skilled in the art to practice the invention and are merely illustrative of the invention. The examples are not to be construed as limiting the scope of the invention as defined in the claims. EXAMPLES [0084] All solvents and reagents were obtained from commercially available sources and used in the manner received. ANALYTICAL MEASUREMENTS [0085] ESI-TOF MS: The electro-sprinkler (ESI) time-of-flight MS (TOF) analysis was performed on an Applied Biosystems Mariner instrument. The instrument operated in positive ion mode. The instrument was mass calibrated with a Petition 870190055152, of 06/14/2019, p. 12/30 26/62 standard solution containing lysine, angiotensinogen, bradykinin (fragment 1-5) and des-Pro bradykinin. This mixture provides a seven point calibration from 147 to 921 m / z. The applied voltage parameters were optimized from a signal obtained from the same standard solution. For accurate mass measurements of poly (ethylene glycol) (PEG), with a nominal Mn value of 400 Da, it was added to the sample of interest and used as an internal mass standard. Two PEG oligomers that grouped the mass of the sample of interest were used to calibrate the mass balance. Samples were prepared as solutions of 30 pM in isopropanol (IPA) with the addition of 2% by volume NaCl saturated in EPA. The samples were directly introduced into the MS ESI-TOF instrument at a rate of 35 pL / minute. Sufficient resolving power (6,000 RP m / Ám FWHM) was obtained in the analysis to obtain the monoisotopic mass for each sample. In each analysis, the experimental monoisotopic mass was compared with the theoretical monoisotopic mass as determined by the respective elementary compositions. In each analysis, the monoisotopic mass comparison was less than 10 ppm error. It should be noted that samples discharged have a sodium atom (Na) included in their elemental composition. This Na atom occurs as a necessary filler added in the sample preparation procedure. Some samples do not require an added filler, as they contain a charge of quaternary nitrogen inherent in their respective structure. [0086] GC: Gas chromatography was performed using a Hewlett Packard HP 6890 Series GC system. Purity was determined by integration of the primary peak and comparison with standard chromatography. [0087] NMR: 1 H NMR characterization was performed using a 400 MHz Varian spectrometer using standard techniques in the technology. Samples were dissolved in chloroform-d (99.8% atomic D), unless otherwise noted. Chemical shifts were determined by designating the residual chloroform peak at 7.25 ppm. Peak areas and proton ratios were determined by integrating peaks separate from the baseline. Division patterns (s = singlet, d = doublet, t = triplet, q = quartet, m = multiples, br = broad) and constants of Petition 870190055152, of 06/14/2019, p. 12/31 27/62 coupling (J / Hz) are reported when present and clearly distinguishable. [0088] Mechanical properties and oxygen permeability: Modulus and elongation tests were conducted according to ASTM D-1708a, using an Instron instrument (Model 4502) where the hydrogel film sample is immersed in borate buffered saline; an appropriate size of the film sample is the length of the measuring base 22 mm and width 4.75 mm, where the sample additionally has ends forming a dog bone to accommodate the clamped sample grip of the Instron instrument, and a thickness of 200 + 50 microns. [0089] Oxygen permeability (also referred to as Dk) was determined by the following procedure. Other methods and / or instruments can be used, as long as the oxygen permeability values obtained from them are equivalent to that of the described method. The oxygen permeability of silicone hydrogels is measured by the polarographic method (ANSI Z80 20-1998) using a 02 Permeometer Model 201T instrument (Createch, Albany, California USA) with a probe containing a central circular gold cathode at its end and a silver anode isolated from the cathode. Measurements are made only on pre-inspected flat silicone hydrogel film samples without pinhead holes, of three different center thicknesses ranging from 150 to 600 microns. Center thickness measurements of the film samples can be made using a meter electronic thickness Rehder ET-I. [0090] Generally, the film samples are in the shape of a circular disc. Measurements are made with the film sample and probe immersed in a bath containing circulating phosphate buffered saline (PBS) balanced at 35 ° C +/- 0.2 °. Before immersing the probe and film sample in the PBS bath, the film sample is placed and centered on the catheter pre-moistened with the balanced PBS, ensuring that there is no air bubble or excess PBS between the cathode and the sample of the film, and the film sample is then attached to the probe with a mounting cap, with the cathode portion of the probe in contact with the film sample only. For silicone hydrogel films, it is often used to employ a Teflon polymer membrane, for example, with a circular disc shape, between the cathode of the Petition 870190055152, of 06/14/2019, p. 12/32 28/62 probe and the film sample. In such cases, the Teflon membrane is first placed on the pre-moistened cathode, and then the film sample is placed on the Teflon membrane, ensuring that there is no air bubble or excess PBS below the Teflon membrane or sample of the movie. Once measurements are collected, only data with a correlation coefficient (R2) value of 0.97 or greater should be entered in the calculation of the Dk value. At least two Dk measurements per thickness and R2 value are obtained. Using known regression analyzes, oxygen permeability (Dk) is calculated from film samples of at least three different thicknesses. Every sample of the film hydrated with solutions other than PBS is first soaked in purified water and naturally balanced for at least 24 hours, and then soaked in PHB and naturally balanced for at least 12 hours. Instruments are regularly cleaned and regularly calibrated using RGP standards. The upper and lower limits are established by calculating a variation of +/- 8.8% of the Repository values established by William J. Benjamin, et al., The Oxygen Permeability of Reference Materials, Optom Vis Sci 7 (12s): 95 (1997) , the disclosure of which is incorporated here in its entirety: NAME OFMATERIAL REPOSITORY VALUES INFERIOR LIMIT UPPER LIMIT Fluorperm 30 26.2 24 29 Menicom EX 62.4 56 66 Quantum II 92.9 85 101 ABBREVIATIONS: NVP 1-Vinyl-2-pyrrolidone TRIS 3-methacryloxypropyltris (trimethylsiloxy) silane HEMA 2-hydroxyethyl methacrylate v-64 2,2'-Azobis (2-methylpropionitrile) EGDMA ethylene glycol dimethacrylate B HT butylated hydroxytoluene SA monomer Petition 870190055152, of 06/14/2019, p. 12/33 29/62 [0091] Ma2D37 [0092] [0093] • σ VI-MCR-C 12 ch 3 Vac-MCR-C 12 or (Va-MCR-C 12) o An 'CHj Unless otherwise specifically stated or clarified by all the numbers used in the examples, their use should be considered, modified by the term about and be a percentage by weight. GENERAL SYNTHETIC SCHEME FOR M1 - (EDS) n- TMS V to fOO EXAMPLE 1. SYNTHESIS OF M 1 - EDS7- TMS SYNTHETIC SCHEME FOR M1 - EDS7- TMS I -b n · I III ÉDIT- ΓΜ5 Petition 870190055152, of 06/14/2019, p. 12/34 30/62 [0095] 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (19.2 g, 0.12 mol) was taken in 50 ml of dry cyclohexane under N2 and stirred for 30 minutes at 25 o C. To this mixture, lithium trimethylsilanolate (1.92 g, 0.02 mol) was added with stirring. After 1 hour dry THF (25 mL) was added and the reaction mixture continued to stir for 24 hours at 25 ° C. [0096] Dimethylchlorosilane (1.9 g, 0.02 mol) was then added and a color change was observed. Stirring was continued for 3 more hours and the reaction mixture was then filtered. The filtrate was concentrated in vacuo to give clear oil in 22 g yield as the expected product based on the preparation method and characterized by NMR, SEC and MALDI showing about 7 2,2,5,5 ring opening units -tetramethyl-2,5-disyl-1-oxacyclopentane condensate. The filtrate was used as is for hydrosilylation taking in toluene (20 mL) and adding allyl methacrylate (3.15 g, 0.025 mol, ~ 25 mmol) under an atmosphere of N2 followed by the addition of a 3% solution by weight of the platinum (O) complex 1,3-divinyl-1,3,3-tetramethyl disiloxane in xylene (as catalyst). The reaction mixture was stirred for 6 hours at 40-45 ° C. Removing the solvent in the rotovap and then under high vacuum to give a yellow oil with 17 g yield as the desired product M 1-EDS7-TMS characterized by MALDI. EXAMPLE 2. M SYNTHESIS OF M 1- EDS6- TMS [0097] In a 2 L neck two-necked flask dried in the oven equipped with a magnetic stir bar and condenser under N2 atmosphere, 2,2,5 were added, 5-tetramethyl-2,5-disyl-1-oxacyclopentane (77.22 g, 0.482 mol) and anhydrous cyclohexane (150 mL) under stirring in an N2 atmosphere. Lithium trimethyl silanolate (7.2 g, 0.0749 mol) was added to the previous reaction mixture followed by the addition of cyclohexane (25 mL). After stirring for one hour, THF (70 mL, distilled with Na / Benzophenone) was added and the reaction mixture continued to stir for 16 hours. Methylacryloxypropyl dimethylchlorosilane (20 g, 0.09 mol) was then added and the mixture stirred for an additional 24 hours. The reaction mixture was then filtered and Silica gel (3.5 g, dried at 160 ° C for 3 hours) was then added and the reaction mixture stirred for an additional 4 hours. The reaction mixture was then filtered through a Petition 870190055152, of 06/14/2019, p. 12/35 31/62 bed of Celite (20 g) and BHT (5 mg) was added to the filtrate. The filtrate was then concentrated in vacuo (40 ° C / 0.3 mm Hg). Heptane (200 ml) was then added to the concentrate with stirring and washed with DI water (100 ml), aqueous NaHCO3 (2 x 100 ml, prepared by dissolving 10 g of NaHCO3 in 200 ml of DI water), brine (100 ml) and finally DI water (100 mL). Heptane (50 mL) was then added and dried over MgSO4 (15 g) for 20 hours. MgSO4 was filtered off and the solvent was removed on a rotary evaporator. The crude product was stirred over basic activated alumina (30 g for 24 hours) and then filtered over a bed of fine Celite. The removal of any solvent from the residue at 25 ° C at 0.2 mmHg for 30 minutes yielded the desired product Ml-EDS6-TMS as a clear oil in 80 g of quantity. This was characterized by NMR, GPC, GC-MS and MALDI. EXAMPLE 3. SYNTHESIS OF M 1- EDS9-TMS [0098] 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (14.4 g, 0.09 mol) was taken in 35 ml of cyclohexane dried under N2 and stirred for 10 minutes at 25 ° C. To this, lithium trimethylsilanolate (960 mg, 0.01 mol) was added with stirring. After 2 hours dry THF (20 mL) was added and the reaction mixture continued to stir for 24 hours at 25 ° C. Chlorodimethylsilylpropyloxy methacrylate (2.20 g, 0.01 mol) was then added and a color change was observed. Stirring was continued for a further 24 hours and the reaction mixture was then terminated with 10 mg NaHCO3. Cyclohexane (10 mL) was added with continued to stir for 2 more hours. The reaction mixture was then filtered over Celite. The filtrate was concentrated in vacuo to give clear oil in 16 g yield as the expected product M1-EDS9-TMS based on the preparation method and characterized by NMR, SEC and MALDI. EXAMPLE 4. SYNTHESIS OF M 1 - EDS 12-TMS [0099] 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (19.2 g, 0.12 mol) was taken in 50 ml of cyclohexane dried under N2 and stirred for 30 minutes at 25 ° C. To this mixture, lithium trimethylsilanolate (960 mg, 0.01 mol) was added with stirring. After 2 hours dry THF (20 mL) was added and the reaction mixture continued to stir for 24 hours at 25 ° C. Chlorodimethylsilylpropyloxy methacrylate (2.20 g, 0.01 mol) was then added and a color change was observed. Stirring continued for 24 hours Petition 870190055152, of 06/14/2019, p. 12/36 32/62 more and the reaction mixture was then filtered over Celite. The filtrate was concentrated in vacuo to give clear oil in 20 g of yield as the expected product Ml-EDS 12-TMS based on the preparation method and characterized by NMR, SEC and MALDI. EXAMPLE 5. SYNTHESIS OF M 1 - EDS 15-TMS [0100] 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (24 g, 0.15 mol) was taken in 60 ml of cyclohexane dried under N2 and stirred for 10 minutes at 25 ° C. To this lithium trimethylsilanolate (960 mg, 0.01 mol) was added with stirring. After 2 hours dry THF (20 mL) was added and the reaction mixture continued to stir for 24 hours at 25 ° C. Chlorodimethylsilylpropyloxy methacrylate (2.20 g, 0.01 mol) was then added and a color change was observed. Stirring was continued for a further 24 hours and the reaction mixture was then terminated with 10 mg of NaHCCb. Cyclohexane (10 mL) was added with continued stirring for 2 more hours. The reaction mixture was then filtered over Celite. The filtrate was concentrated in vacuo to give transparent oil in 25 g yield as the expected product M 1 - EDS 15-TMS based on the preparation method and characterized by NMR, SEC and MALDI. EXAMPLE 6. SUMMARY OF M1-BIS-EDS3-TMS l s ® -Si-0 Li I [0101] Lithium trimethyl silanolate (19.7 g, 0.2 mol) was suspended in anhydrous hexane (100 mL) in a 500 mL round bottom flask and equipped with a mechanical stirrer, argon gas and a funnel drip. A solution of 2,2,5,5tetramethyl-2,5-disyl-1-oxacyclopentane (32.07 g, 0.2 mol) in anhydrous hexane (100 ml) was quickly added to the flask with stirring. After one hour, the flask was cooled in an ice bath and DMF (50 ml) was added with continued stirring. After 4 hours, 3-methacryloxypropyl methyldichlorosilane (29 g, 0 12 mol) was added dropwise to the reaction mixture. The reaction mixture was stirred Petition 870190055152, of 06/14/2019, p. 37/123 33/62 additionally for 24 hours at room temperature. Deionized water (50 ml) was then added to the flask with stirring. The organic layer was separated and dried over anhydrous sodium sulfate and filtered. The solvent was evaporated on a rotovap to give the desired product Ml BIS-EDS3-TMS in 40 g of quantity as a light yellowish oil. The product was characterized by GC, GC / MS, IR and NMR. EXAMPLE 7. SYNTHESIS OF DIMETHYLAMONIUM METHACRYLAMIDE (MA1-Q-EDS9TMS) n [0102] where n is 9 [0103] 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (48 g, 0.3 mol) was taken in 55 ml of dry cyclohexane under N2 and stirred for 30 minutes at 25 ° C. To this, lithium trimethylsilanolate (48 g, 0.05 mol) was added with stirring. After 1 hour, dry THF (25 mL) was added and the reaction mixture continued to stir for 24 hours at 25 ° C. [0104] Dimethylchlorosilane (5.1 g, 0.55 mol) was then added and a color change was observed. Stirring was continued for 3 more hours and the reaction mixture was then filtered. [0105] The filtrate was concentrated in vacuo to give transparent oil in 42 g of yield as the expected product based on the preparation method and characterized by NMR, SEC and MALDI. 28.0 g of this was used for hydrosilylation taking in toluene (30 ml) and adding 1-bromobutene (4 g, 0.03 mol,) under NT atmosphere followed by the addition of a 3% solution by weight of the platinum (O) complex 1,3-divinyl-1, 1,3,3-tetramethyl disiloxane in xylene (100 µl as catalyst) the reaction mixture was stirred for 4 hours at 45-50 ° C and then at 25 ° C for 48 hours. The reaction mixture was filtered over Celite using a cotton plug. [0106] Removal of the solvent in the rotovap and then high vacuum gave a yellow oil in 27 g of yield as trimethylsilyloxy- [oly (dimethylsilyl-ethyl-dimethylsilyloxy)] Petition 870190055152, of 06/14/2019, p. 12/38 34/62 dimethylsilylbutylbornide of the desired bromine compound characterized by MALDI with n = ~ 9 units. [0107] 6.6 g (0.004 mol) of the bromine compound and 680 mg (0.004 mol) of dimethylaminopropyl methacrylamide were mixed with each other and stirred under NT for 6 hours at 25 ° C. A certain exotherm was observed. The reaction mixture was subjected to high vacuum after 10 hours to give the desired product MA1-Q-EDS9TMS in almost quantitative yield and characterized by NMR and MALDI. EXAMPLE 8. SYNTHESIS OF M1-MCR- C12 MONOFunctional COMPARATIVE Π [0108] where right 11. [0109] Finished ethoxypropyl hydroxy polydimethylsiloxane (50 grams, 0.048 mol) available from Gelest, Inc. (MCR-C 12) was added to a 500 mL round-bottom flask and dried by toluene azeotropic distillation. Anhydrous methylene chloride (200 mL) and triethylamine (17.12 g, 0.17 mol) were added to the flask and the reaction was stirred for 20 minutes. The reaction flask was equipped with an addition funnel which was charged with methacryloyl chloride (17.18 g, 0.16 mol) and an additional 85 ml of anhydrous methylene chloride. The contents of the addition funnel were added to the reaction mixture dropwise at which time the addition funnel was exchanged with a reflux condenser. The reaction was then refluxed for 4 hours. After cooling the reaction mixture was filtered and placed in a separatory funnel where it was washed twice with 0.1 N HCI (150 mL); 2 times with sodium bicarbonate solution (150 ml) and 2 times with brine solution (150 ml). The organic layer was then stirred with 10 grams of deodorant carbon and 10 grams of silica gel for 24 hours and was then filtered and dried on a rotovap. The reaction yielded 45 g of a light yellow oil M1-MCR-C 12 which was characterized by GC, NMR, and MALDI. EXAMPLE 9. SYNTHESIS OF MCAI-MCR-C 12 MONO-FUNCTIONAL COMPARATIVE Petition 870190055152, of 06/14/2019, p. 12/39 35/62 [0110] where n is 11. [0111] Finished ethoxypropyl hydroxy polydimethylsiloxane (200 grams, 0.193 mol) available from Gelest, Inc. (MCR-C 12) was added to a 2 L round-bottom flask and dried by azeotropic toluene distillation. Anhydrous methylene chloride (500 ml) and dibutyltin dilaurate (0.474 g, 0.0007 mol) were added to the flask. The reaction flask was equipped with an addition funnel that was loaded with 2-isocyanatoethyl methacrylate (45.0 g, 0.290 mol) and an additional 100 mL of anhydrous methylene chloride. The contents of the addition funnel were then added to the reaction mixture dropwise and the reaction was stirred for 48 hours. 50 grams of silica gel (EMD Silica gel 60) was then added to the reaction mixture and stirred for 24 hours to clean excess isocyanatoethyl methacrylate. The reaction mixture was then filtered and concentrated in a rotovap yielding 210 g of a transparent MCAI -MCR-C 12 oil which was characterized by GC, NMR, and MALDI. 1. Formulation of various monomers based on EDS and comparative examples Petition 870190055152, of 06/14/2019, p. 40/123 Example Methacrylamide crosslinkerMa2D37 TRIS [methacrylate oftris (trimethylsiloxy) silylpropyl] N-vinyl pyrrolidone N, N-dimethylacrylamide 2-hydroxyethyl methacrylate Hexanol M1-MCR-C12 MCa1-MCR-C12 M1-EDS7-TMS M1-EDS6-TMS M1-EDS9-TMS M1-EDS12-TMS M1-EDS15-TMS M2-EDS23 M2-D27-EDS10 M1-Bis-D3-TMS M1-Bis-EDS3-TMS Ma1-Q-EDS9-TMS V1-MCR-12 VCa1-MCR — C12 Darocur 1123 IMVT (concentration in ppm) 10 9.5 35.5 30.8 4.7 4.7 4.7 9.5 x x x x x x x x x x x x x 0.47 90 11 95 35.5 30.8 4.7 4.7 0.7 x 9.5 x x x x x x x x x x x x 0.47 93 12 9.5 35.5 30.8 4.7 4.7 4.7 x x 9.5 x x x x x x x x x x x 0.47 90 13 9.5 35.5 30.8 4.7 4.7 4.7 x x x 9.5 x x x x x x x x x x 007 90 14 9.5 35.5 30.8 4.7 4.7 4.7 x x x x 9.5 x x x x x x x x x 0.47 90 15 9.5 35.5 30.8 47 4.7 4.7 x x n x x 9.5 x x x x x x x x 0.47 90 16 9.5 35.5 30.8 47 4.7 4.7 x x x x x x 9.5 x x x x x x x 0.47 90 17 0.0 29.9 25.9 4.0 4.0 19.9 x x x x 8.0 x x 8.0 x x x x x x 0.97 90 18 00 32.5 28.1 4.3 4.3 13.0 x x x x 8.7 x x x 8.7 x x x x x 0.07 90 19 9.5 35.5 30.8 4.7 4.7 4.7 x x x x x x x x x 9.5 x x x x 0.47 90 20 9.5 35.5 30.8 4.7 0.7 4.7 x x x x x x x x x x 9.5 x x x 0.47 90 21 9.5 35.5 30.8 0.7 4.7 4.7 x x x x x x x x x x x 9.5 x x 0.47 90 22 9.5 355 30.8 4.7 4.7 4.7 x x x x x x x x x x x x 9.5 x 0.47 90 23 9.5 35.5 30.8 4.7 47 47 x x x x x x x x x x x x x 9.5 0.47 90 Note: The quantities shown in the coloring are in ppm. previous are percentages by weight in the formulation. Level of 35/62 Petition 870190055152, of 06/14/2019, p. 41/123 37/62 PREPARATION PROCEDURE: [0112] For examples 10-15, 17-23, 32, 54-56, 69 and 70, the specific monomer mixtures presented were prepared according to table 1 above and tables 3, 5 and 6 below, weighing various percentages by weight of the components. The monomer mixture was dispensed between polypropylene molds and prepared as lenses or smooth surfaces in the case of Dk samples. Polymerization was carried out under UV light (-350 nm) for a period of two hours. After polymerization, the lenses or smooth surfaces were released from the molds using 33% IPA in water and then extracted in 100% IPA for 4 hours. Lenses / smooth surfaces were then placed in deionized water for 30 minutes and packaged in flasks containing 4 mL of borate buffered saline (BBS). The measured properties for the lenses / smooth surfaces are shown in the table below. Table 2: Selected characteristics of processed lenses / smooth surfaces containing EDS monomers and comparative examples. Example Water content(%) Dk (barriers) Module (gm / mm 2 ) Stretching(%) Tear resistance (gm / mm) Angle ofcontact fromadvance Angle ofcontact fromsetback Hysteresis 10 42.3 96 92 (10) 125 (52) 7 (1) 28 (4) 19 (0) 9 (4) 11 43.0 x 107 (10) 100 (30) 4 (1) 29 (2) 21 (1) 8 (1) 12 47.3 93 58 (6) 100 (30) 4 (1) 29 (2) 21 (1) 8 (1) 13 40.8 87 91 (9) 117 (25) 5 29 (3) 21 (3) 8 (6) 14 42.1 x .3 / 17 .3 / 17 .3 / 17 x x x 15 35.7 x .3 / 17 .3 / 17 .3 / 17 x x x 17 42.0 95 74 (4) 236 (25) 7 (1) x x x 18 41.6 85 66 (5) 143 (43) 6 (1) 19 40.9 x 137 (6) 157 (22) x x x x 20 32.0 x 137 (8) 137 (20) x x x x 21 43.1 x 140 (6) 96 (14) x x x x 22 41.9 x 98 (10) 159 (29) 6 (0.4) 98 (2) 21 (1) 76 (1) 23 39.2 x 105 (5) 125 (23) 5 (1) 96 (5) 21 (1) 76 (5) 32 46.9 91 71 (8) 165 (74) x 31 (6) 16 (1) 15 (5) 54 44.9 x 84 (10) 177 (31) 4 (1) 33 (0.7) 19 (1.0) 14 (1.6) 55 43.2 x 80 (7) 176 (60) 7 (1) 40 (7.0) 24 (2.3) 16 (9.2) 56 43.3 x 72 (4) 159 (68) 7 (0.3) 41 (2.0) 22 (1.4) 19 (0.6) Petition 870190055152, of 06/14/2019, p. 42/123 38/62 69 32.0 x 137 (8) 137 (20) x x x x 70 43 85 77 (6) 200 (24) 5 (0.2) 39 (9.7) 22 (1.5) 17 (10.9) [0113] A 4502 Mechanical Tester MTS Instron was used to measure the modulus, strength limit, percentage elongation and tear resistance of the lenses. The samples were tested in a water bath containing saline buffered with borate. [0114] Captive bubble contact angle data was collected on a First Ten Angstroms FTA-1000 Drop Shape Instrument. All samples were washed in HPLC grade water before analysis to remove components of the packaging solution from the sample surface. Before data collection, the surface tension of the water used for all experiments was measured using the drop-drop method. In order to qualify the water as suitable for use, a surface tension value of 70 - 72 dynes / cm was expected. All lens samples were placed in a curved sample holder and submerged in a quartz cell filled with HPLC grade water. The contact angles of the captive forward and reverse bubble were collected for each sample. The withdrawal contact angle is defined as the angle measured in water as the air bubble expands across the sample surface (water recedes from the surface). The forward contact angle is defined as the angle measured in water as the air bubble retracts from the lens surface (water advances through the surface). All captive bubble data were collected using a high-speed digital camera focused on the sample / air bubble interface. The contact angle was calculated on the digital board immediately before the movement of the contact line through the sample / air bubble interface. Table 3. Additional examples of monomer blend formulations Petition 870190055152, of 06/14/2019, p. 43/123 39/62 Example Crosslinkermethacrylamide Ma2D37 TRIS [tris (trimethylsiloxide) silylpropyl methacrylate] N-vinyl pyrrolidone N, N-dimethylacrylamide 2- Methacrylatehydroxyethyl Hexanol M1-eDS6-TMS Darocur 1173 IMVT (concentration in ppm) 24 0.1 41.2 58.1 0.0 0.0 0.0 0.1 0.48 90 25 4.7 38.4 29.2 1.9 7.6 4.4 13,3 0.47 90 26 7.0 30.5 20.5 3.0 7.0 4.7 27,0 0.48 90 27 11.1 29.4 27.7 2.6 6.0 4.0 18,8 0.43 90 28 32.3 28.0 13.8 4.3 4.3 4.0 12,9 0.43 90 29 44.7 12.9 23.0 0.0 4.2 3.9 10,9 0.42 90 30 59.7 9.6 14.3 0.0 4.8 4.5 6.7 0.48 90 31 75.8 0.0 0.0 9.5 9.5 4.7 0.1 0.47 90 32 6.6 35.5 30.8 4.7 4.7 4.7 12,3 0.47 90 33 4.5 9.0 58.8 4.5 0.0 13,6 9.1 0.45 90 34 6.1 18.2 18.2 1.2 1.2 48,6 6.1 0.30 90 35 7.7 23.1 23.1 1.5 1.5 34,6 7.7 0.48 90 36 15.9 15.9 23.9 4.0 4.0 19, 15, 0.40 90 Petition 870190055152, of 06/14/2019, p. 44/123 40/62 9 9 37 5.0 10.0 29.9 5.0 5.0 'τγ σ>Έ— 29,9 0.50 90 Note: The quantities shown in the previous table are percentages by weight in the formulation. Coloring level is in ppm. Table 4. Additional examples of monomer blend formulations Example Crosslinkermethacrylamide Ma2D37 TRIS [methacrylate oftris (trimethylsiloxide) silylpropyl] N-vinyl pyrrolidone N, N-dimethylacrylamide 2-hydroxyethyl methacrylate Hexanol M1-eDS6-TMS Darocur 1173 IMVT (concentration in ppm) 38 0.1 41.2 58.1 0.0 0.0 0.0 0.1 0.48 145 39 4.7 38.4 29.2 1.9 7.6 4.4 13.3 0.47 145 40 7.0 30.5 20.5 3.0 7.0 4.7 27.0 0.48 145 41 11.1 29.4 27.7 2.6 6.0 4.0 18.8 0.43 145 42 32.3 28.0 13.8 4.3 4.3 4.0 12.9 0.43 145 43 44.7 12.9 23.0 0.0 4.2 3.9 10.9 0.42 145 44 59.7 9.6 14.3 0.0 4.8 4.5 6.7 0.48 145 45 75.8 0.0 0.0 9.5 9.5 4.7 0.1 0.47 145 46 6.6 35.5 30.8 4.7 4.7 4.7 12.3 0.47 145 47 4.5 9.0 58.8 4.5 0.0 13.6 9.1 0.45 145 48 6.1 18.2 18.2 1.2 1.2 48.6 6.1 0.30 145 49 7.7 23.1 23.1 1.5 1.5 34.6 7.7 0.48 145 50 15.9 15.9 23.9 4.0 4.0 19.9 15.9 0.40 145 51 5.0 10.0 29.9 5.0 5.0 14.9 29.9 0.50 145 Note: The quantities shown in the previous table are percentages by weight in the formulation. Coloring level is in ppm. Petition 870190055152, of 06/14/2019, p. 45/123 41/62 Table 5. Additional examples of monomer blend formulations Example Crosslinkermethacrylamide Ma2D37 TRIS [methacrylate oftris (trimethylsiloxide) silylpropyl] N-vinyl pyrrolidone N, N-dimethylacrylamide 2-hydroxyethyl methacrylate Hexanol Nonanol t-amolic alcohol M1-EDS6-TMS M1-BIS-EDS3-TMS Darocur 1173 IMVT (concentration in ppm) 52 0.1 41.2 58.1 0.0 0.0 0.0 5.1 0.0 0.1 0.0 0.1 200 53 4.7 38.4 29.2 1.9 7.6 4.4 4.4 0.0 13.3 0.0 0.47 200 54 6.6 35.6 30.8 4.7 4.7 4.7 0.0 0.0 12.3 0.0 0.47 200 55 6.6 35.6 30.8 4.7 4.7 0.0 4.7 0.0 12.3 0.0 0.47 200 56 6.6 35.6 30.8 4.7 4.7 0.0 0.0 4.7 12.3 0.0 0.47 200 57 7.0 30.5 20.5 3.0 7.0 0.0 4.7 0.0 27.0 0.0 0.48 200 58 11.1 29.4 27.7 2.6 6.0 4.0 0.0 0.0 18.8 0.0 0.43 200 59 32.3 28.0 13.8 4.3 4.3 0.0 0.0 4.0 12.9 0.0 0.43 200 60 44.7 12.9 23.0 0.0 4.4 0.0 3.9 0.0 10.9 0.0 0.2 200 61 59.7 9.6 14.3 0.0 4.8 0.0 0.0 4.5 6.7 0.0 0.48 200 62 75.8 0.0 0.0 9.5 9.5 4.7 0.0 0.0 0.1 0.0 0.47 200 63 6.6 35.5 30.8 4.7 4.7 4.7 0.0 0.0 12.3 0.0 0.47 200 64 4.5 9.0 58.8 4.5 0.0 0.0 13.6 0.0 9.1 0.0 0.45 200 65 6.1 18.2 18.2 1.2 1.2 0.0 0.0 48.6 6.1 0.0 0.30 200 66 7.7 23.1 23.1 1.5 1.5 34.6 0.0 0.0 7.7 0.0 0.48 200 67 15.9 15.9 23.9 4.0 4.0 0.0 19.9 0.0 15.9 0.0 0.40 200 68 5.0 10.0 29.9 5.0 5.0 0.0 0.0 14.9 29.9 0.0 0.50 200 69 9.5 35.5 30.8 4.7 4.7 4.7 4.7 0.0 0.0 9.5 0.47 60 Note: The quantities shown in the previous table are percentages by weight in the formulation. Coloring level is in ppm. Table 6. Additional examples of monomer blend formulations Petition 870190055152, of 06/14/2019, p. 46/123 42/62 Example Methacrylamide crosslinkerMa2D37 TRIS [methacrylate oftris (trimethylsiloxide) silylpropyl] N-vinyl pyrrolidone N, N-dimethylacrylamide 2-hydroxyethyl methacrylate Hexanol Nonanol t-amolic alcohol M1-EDS6-TMS M1-BIS-EDS3-TMS Darocur 1173 IMVT (concentration in ppm) 70 7.0 34.6 30.6 4.7 4.7 0.0 4.7 0.0 12.6 0.6 0.5 200 71 9.5 35.5 35.3 7.7 4.7 4.7 4.7 0.0 0.0 2.0 0.47 200 72 0.1 41.2 58.1 0.0 0.0 0.0 5.1 0.0 0.1 0.5 0.1 200 73 4.7 38.4 29.2 1.9 7.6 4.4 4.4 0.0 13.3 1.1 0.47 200 74 6.6 35.6 30.8 4.7 4.7 4.7 0.0 0.0 12.3 0.0 0.47 200 75 6.6 35.6 30.8 4.7 4.7 0.0 4.7 0.0 12.3 0.0 0.47 200 76 6.6 35.6 30.8 4.7 4.7 0.0 0.0 4.7 12.3 0.0 0.47 200 77 7.0 30.5 20.5 3.0 7.0 0.0 4.7 0.0 27.0 0.0 0.48 200 78 11.1 29.4 27.7 2.6 6.0 4.0 0.0 0.0 18.8 0.0 0.43 200 79 32.3 28.0 13.8 4.3 4.3 0.0 0.0 4.0 12.9 0.0 0.43 200 80 44.7 12.9 23.0 0.0 4.4 0.0 3.9 0.0 10.9 0.0 0.2 200 81 59.7 9.6 14.3 0.0 4.8 0.0 0.0 4.5 6.7 0.0 0.48 200 82 75.8 0.0 0.0 9.5 9.5 4.7 0.0 0.0 0.1 0.0 0.47 200 83 6.6 35.5 30.8 4.7 4.7 4.7 0.0 0.0 12.3 0.0 0.47 200 84 4.5 9.0 58.8 4.5 0.0 0.0 13.6 0.0 9.1 0.0 0.45 200 85 6.1 18.2 18.2 1.2 1.2 0.0 0.0 48.6 6.1 0.0 0.30 200 86 7.7 23.1 23.1 1.5 1.5 34.6 0.0 0.0 7.7 0.0 0.48 200 Note: The quantities shown in the previous table are percentages by weight in the formulation. Coloring level is in ppm. EXAMPLE 87. EDS capping with chlorodimethyl (3- (2,2,3,3,4,4,5,5octafluorpentyloxy) propyl) silane Step 1 Petition 870190055152, of 06/14/2019, p. 47/123 43/62 Pt · 'Si catalyst ----------> ΙΉΈ, tohietio I / F F F H chlorodimethyl (3- (2,2,3,3,4,4,5,5-octafluorpentyloxy) propyl) silane Substance Amount Dimethylchlorosilane 120 mL allyloxioctafluorpentane 200 g Pt / Si Catalyst 640 pL Anhydrous Toluene 250 mL Anhydrous tetrahydrofuran 250 mL [0115] In a 1,000 mL three-necked round-bottom flask equipped with a reflux condenser, thermocontroller, magnetic stirrer and argon gas blanket, a mixture of dimethylchlorosilane, toluene and THF was added to the flask. Platinum (0) -1,3-divinyl-1, 1,3,3-tetramethyl disiloxane was then added. The flask was heated to 60 ° C for 7 hours. The reaction mixture became exothermic at about 85 ° C after about half an hour. A sample was taken from the flask and checked by GC and had little starting material. The reaction continued to run for about seven hours. Chlorodimethyl (3- (2,2,3, 3,4,4,5, 5octafluorpentyloxy) propyl) silane was vacuum distilled at 70-80 ° C. Step II o I H a Of tying éiatiliccTHF O J .OH j> BuLi Si -------- 1 AÍA I I. F 3 T'9,Ç.10 Ή 3-methacryloxypropyldimethylhydroxysilane-EDS10-dimethylsilypropyloxytafluorpentane [0116] Deionized water (100 ml) and diethyl ether (200 ml) were added to a 500 ml round-bottomed flask with a single neck equipped with a stirrer Petition 870190055152, of 06/14/2019, p. 48/123 44/62 magnetic. The flask was cooled in an ice bath at 0 ° C. The flask was equipped with a drip funnel and a mixture of (10 g, 0.045 mol) of 3-methacryloxypropyl dimethylchlorosilane and 50 ml of anhydrous THF was added to the flask, the reaction was stirred for one hour at 0 ° C. the organic layer was separated and dried over anhydrous sodium sulfate and filtered. The solvent was evaporated on a rotovap to give 3 methacryloxypropyl dimethylhydroxysilane in 9.0 g amount, 99% yield as a clear colorless oil. [0117] 3-Methacryloxypropyl dimethylhydroxysilane (4 g, 0.02 mol) was added to a 500 mL single-necked round-bottom flask equipped with a magnetic stirrer. A 2.5 M n-BuLi (0.006 mol) mixture was slowly added to the flask. A mixture of 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (65.3 g, 0.4 mol) and THF (50 ml) was added to the flask. The reaction was stirred for 24 hours. Chlorodimethyl (3 (2,2,3,3,4,4,5,5-octafluorpentyloxy) propyl) silane (7.1 g, 0.02 mol) was added to the flask and stirred for 24 hours. The solvent was evaporated on a rotovap to give 3methacryloxypropyl dimethylsilyloxy-EDS 10-dimethylsilylpropyloxytatapuorpentane in 38 g amount, 90% yield as a clear colorless oil. The sample was checked by NMR, GC-MS and MALDI spectroscopy. EXAMPLE 88. Opening the EDS ring with chlorodimethyl (3- (2,2,3,3,4,4,5,5octafluorpentyloxy) propyl) silane l-0n Petition 870190055152, of 06/14/2019, p. 49/123 45/62 Step I [0118] In a 250 ml necked-bottom flask equipped with a magnetic stirrer under nitrogen gas in an ice bath, water and ether were added and stirred. Chlorodimethyl (3- (2,2,3,3,4,4,5,5-octafluorpentyloxy) propyl) silane and THF were added to a dropping funnel and added dropwise to the water / ether mixture. The reaction was stirred at 0 ° C for one hour. The product mixture was extracted with ether, dried over sodium sulfate, filtered and the ether was processed on the rotovap. The product of 3-dimethyl (3- (2,2,3, 3,4,4,5,5-octafluorpentyloxy) propyl) silanol was used in the next step of the reaction. Step II [0119] In a 500 mL round-bottom flask, equipped with a mechanical stirrer, air gas and a drip funnel; 3-dimethyl (3- (2,2,3,3,4,4,5,5octafluorpentyloxy) propyl) silanol product (7 g, 0.02 mol) was added. A mixture of n-BuLi 2.5 M (0.006 mol) was slowly added to the flask followed by the addition of a solution of 2,2,5,5-tetramethyl-2,5-disyl-1-oxacyclopentane (65 g, 0.4 mol) in THF (50 mL). The reaction continued to stir for 24 hours. 3- (chlorodimethylsilyl) propyl methacrylate (4.84 g, 0.022 mol) was added to the reaction mixture and stirring was continued for another 6 hours. After that, the solvent was evaporated in vacuo to make the product available which was characterized by NMR and MALDI. EXAMPLE 89. Better lubricity by phosphoryl choline coating [0120] For each sample, a 0.5% BBS solution was prepared by adding 1.25 g of polymer to the BBS. The total volume of the solution was 250 ml. The pH of the solutions was 7.2. The test solution was poly (phosphocholine). Comparative solutions comprising separately Poly (acrylic acid) - 450,000 g / mol, Tetronic Tl 107, Tetronic T908, HPMC or Polymer JR were also prepared. All solutions were made at a concentration of 0.5% in BBS and the pH was adjusted to 7.2 if necessary (by standard techniques known in the technology). To test the lens, 4.5 mL of each solution was added to a glass autoclave bottle. A lens containing organosilicon was placed in each vial and the system was capped with a Teflon-coated stapling cap. Each system was then subjected to Petition 870190055152, of 06/14/2019, p. 50/123 46/62 autoclave (121 ° C for 30 minutes). The packaged lens was then removed from the package and washed with DI water. The washed lens was then placed on a polystyrene Petri dish and sectioned with a scalpel in order to make the lens flat. PREFERRED EMBODIMENTS [0121] Certain preferred embodiments of the invention are disclosed here: [0122] 1. A monomer with a structural formula (I): (I) [0123] where X is the residue of a ring opening agent or capping agent; L is the same or different and is a linking group or a bond; V is an ethylenically unsaturated polymerizable group; R1, R2, R3, R4, R5, R6 are independently H, alkyl, halo alkyl, heteroalkyl, alkyl cycle, heterocycle alkyl, alkenyl, halo alkenyl, or aromatic; R7 and Rs when present are independently H or alkyl where at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100. [0124] 2. A monomer with a structural formula (II) tiJJ [0125] where L is the same or different and is a linking group or a bond and V is the same or different and is an ethylenically unsaturated polymerizable group, R1, R2, R3, R4, Rs, R6 and R9 are independently H, alkyl, halo alkyl, alkyl cycle, heterocycle alkyl, alkenyl, halo alkenyl, or aromatic, R7 and Rs are independently H or alkyl where at least one of R7 or Rs is hydrogen, y is 2-7 and n is 1-100. Petition 870190055152, of 06/14/2019, p. 51/123 47/62 [0126] 3. A monomer according to preferred embodiment 1 where ο X is a residue of a ring opening agent selected from the group consisting of alkyl lithiums, alkoxides, trialkylsiloxylites and capped acrylic ester polysiloxane prepolymers in the presence of an acid catalyst. [0127] 4. The monomer of preferred embodiment 3 wherein the ring-opening residue contains halo atoms. [0128] 5. The monomer of preferred embodiment 1 in which the linker group is selected from the group consisting of substituted or unsubstituted alkyl, alkyl ether, alkenyls, alkenyl ethers, haloalkyls, substituted or unsubstituted siloxanes, and monomers capable of propagate the opening of the ring. [0129] 6. The monomer of the preferred embodiment 2 in which the linker group is selected from the group consisting of substituted or unsubstituted alkyl, alkyl ether, alkenyls, alkenyl ethers, haloalkyls, substituted or unsubstituted siloxanes, and monomers capable of propagate the opening of the ring. [0130] 7. The preferred modality monomer 1 with a structural formula (III): [0131] where R9, R10 and R11 are independently H, alkyl, haloalkyl or other substituted alkyl groups, n is 1 -100 and 1 is 0-10. [0132] 8. The monomer of preferred mode 1 with a structural formula (IV): [0133] where n is 1-100. [0134] 9. The preferred mode monomer 8 where n is 2-80. [0135] 10. The preferred mode monomer 8 where n is 3-20. [0136] 11.0 monomer of preferred mode 8 where n is 5-15. [0137] 12. A monomer of preferred mode 1 where V is selected from the Petition 870190055152, of 06/14/2019, p. 52/123 48/62 group consisting of acrylates, methacrylates, vinyl carbonates, 0-vinyl carbamates, N-vinyl carbamates, acylamides and methacrylamides. [0138] 13. A monomer of preferred mode 2 where V is selected from the group consisting of acrylates, methacrylates, vinyl carbonates, 0-vinyl carbamates, N-vinyl carbamates, acylamides and methacrylamides. [0139] 14. The monomer of preferred mode 1 with a structural formula selected from the group consisting of the following structural formulas: rrxi. [0140] 15. The preferred modality monomer 1 with a structural formula selected from the group consisting of the following structural formulas: Petition 870190055152, of 06/14/2019, p. 53/123 49/62 RioT-Sr R11 (X), Wr * WN-A H <n txi>, (XII) [0141] where R9, R10 and R11 are independently H, alkyl, haloalkyl or other substituted alkyl groups and n is 1-100 and 1 is 0-10. [0142] 16. The preferred modality monomer 1 with a structural formula selected from the group consisting of the following structural formulas: (XIII), / O (XIVI Petition 870190055152, of 06/14/2019, p. 54/123 50/62 [0143] where n is 1 -100 and X- is a counterion to provide a total neutral charge. [0144] 17. The monomer of preferred embodiment 1 with the following structural formula: ^ r ., O 1 1 1 1 , SL_ 1 (o | O 1 SI1 l OSii 1 1 7 1 J (xvi). [0145] 18. A mixture of monomers used to form a medical device in which the mixture of monomers comprises at least one monomer selected from the group consisting of monomers of preferred modality 1 and, when polymerized, form a medical device. [0146] 19. A mixture of monomers used to form a medical device in which the mixture of monomers comprises at least one monomer selected from the group consisting of monomers of preferred modality 2 and, when polymerized, form a medical device. [0147] 20. The monomer blend of preferred embodiment 18 additionally comprising a second copolymerizable monomer. [0148] 21. The monomer blend of preferred embodiment 19 further comprising a second copolymerizable monomer. [0149] 22. The monomer mixture of the preferred modality 18, in which the medical device formed is selected from the group consisting of rigid contact lenses, soft contact lenses, phakic intraocular lenses, aphakic intraocular lenses and horny implants. [0150] 23. The monomer blend of preferred mode 19 in which the medical device formed is selected from the group consisting of rigid contact lenses, soft contact lenses, phakic intraocular lenses, aphakic intraocular lenses and horny implants. Petition 870190055152, of 06/14/2019, p. 55/123 51/62 [0151] 24. The monomer mixture of the preferred modality 18, in which the medical device formed is selected from the group consisting of artificial heart valves, films, surgical devices, vessel substitutes, intrauterine devices, membranes, diaphragms, surgical implants, artificial blood vessels, artificial ureters, artificial breast tissue, membranes designed to come into contact with body fluid outside the body, membranes for kidney dialysis machines, membranes for heart / lung machines, catheters, mouth guards , denture coatings, ophthalmic devices, and hydrogel contact lenses. [0152] 25. The preferred mode 19 monomer mixture, in which the medical device formed is selected from the group consisting of artificial heart valves, films, surgical devices, vessel substitutes, intrauterine devices, membranes, diaphragms, surgical implants, artificial blood vessels, artificial ureters, artificial breast tissue, membranes intended to come into contact with body fluid outside the body, membranes for kidney dialysis machines, membranes for heart / lung machines, catheters, mouth guards, dentures, ophthalmic devices, and hydrogel contact lenses. [0153] 26. The monomer blend of preferred embodiment 24, wherein the medical device is a hydrogel contact lens. [0154] 27. The monomer blend of preferred mode 25, wherein the medical device is a hydrogel contact lens. [0155] 28. The preferred mode 18 monomer mixture, wherein at least one monomer selected from the group consisting of preferred mode 1 monomers is a polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group. [0156] 29. The monomer blend of preferred embodiment 19, wherein at least one monomer selected from the group consisting of monomers of preferred embodiment 2 is a polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group. Petition 870190055152, of 06/14/2019, p. 56/123 52/62 [0157] 30. The monomer mixture of the preferred embodiment 28, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 0.1 to about 30 weight percent of the monomer mixture . [0158] 31. The monomer blend of preferred embodiment 28, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 0.1 to about 20 weight percent of the monomer mixture. [0159] 32. The monomer mixture of the preferred embodiment 28, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 5 to about 15 weight percent of the monomer mixture. [0160] 33. The monomer blend of preferred embodiment 29, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 0.1 to about 30 weight percent of the monomer mixture. [0161] 34. The monomer mixture of the preferred embodiment 29, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 0.1 to about 20 weight percent of the monomer mixture. [0162] 35. The monomer blend of preferred embodiment 29, wherein the polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group is present in an amount of about 5 to about 15 weight percent of the monomer mixture. [0163] 36. The monomer blend of preferred embodiment 20, wherein the second copolymerizable monomer is a monomer containing hydrophobic silicone. [0164] 37. The monomer blend of preferred embodiment 36, wherein the hydrophobic silicone-containing monomer is present in the monomer blend between about 0.1 to about 75.8 weight percent. [0165] 38. The monomer mixture of the preferred modality 36, in which the Petition 870190055152, of 06/14/2019, p. 57/123 53/62 monomer containing hydrophobic silicone is present in the monomer mixture between about 2 to about 20 weight percent. [0166] 39. The monomer blend of preferred embodiment 36, wherein the hydrophobic silicone-containing monomer is present in the monomer blend between about 5 to about 13 weight percent. [0167] 40. The monomer blend of preferred embodiment 21, wherein the second copolymerizable monomer is a monomer containing hydrophobic silicone. [0168] 41. The monomer blend of preferred embodiment 40, wherein the hydrophobic silicone-containing monomer is present in the monomer blend between about 0.1 to about 75.8 weight percent. [0169] 42. The monomer blend of preferred embodiment 40, wherein the hydrophobic silicone-containing monomer is present in the monomer blend between about 2 to about 20 weight percent. [0170] 43. The monomer blend of preferred embodiment 40, wherein the hydrophobic silicone-containing monomer is present in the monomer blend between about 5 to about 13 weight percent. [0171] 44. The monomer blend of preferred embodiment 20, wherein the second copolymerizable monomer is a hydrophobic monomer containing non-silicone. [0172] 45. The monomer blend of preferred embodiment 21, wherein the second copolymerizable monomer is a hydrophobic monomer containing non-silicone. [0173] 46. The monomer blend of preferred embodiment 20, wherein the hydrophobic monomer containing non-silicone is present at about 0 to about 60 weight percent. [0174] 47. The monomer blend of preferred embodiment 21, wherein the hydrophobic monomer containing non-silicone is present at about 0 to about 60 weight percent. [0175] 48. The monomer mixture of preferred mode 20, in which the hydrophobic monomer containing non-silicone is selected from the group consisting of Petition 870190055152, of 06/14/2019, p. 58/123 54/62 alkyl acrylates and alkyl methacrylates. [0176] 49. The monomer blend of preferred embodiment 21, wherein the hydrophobic monomer containing non-silicone is selected from the group consisting of alkyl acrylates and alkyl methacrylates. [0177] 50. The preferred modality monomer mixture 20, in which the second copolymerizable monomer is a massive monomer selected from the group consisting of methacryloxypropyl tris (trimethylsiloxy) silane (TRIS), pentamethyldisiloxanyl methyl tris (trimethylsilyloxy) , phenyltretramethyl-disloxanylethyl acrylate, methyldi (trimethylsiloxy) methacryloxymethyl silane, [tris (trimethylsiloxy) silyl] propyl vinyl, 3 [tris (trimethylsiloxy) silyl] propyl allyl, and 3- [trisyl trimethylsyl] triol (trimethylsiloxide) and [trisyl] methylate] ) silyl] propyl vinyl. [0178] 51. The mixture of monomers of preferred modality 21, in which the second copolymerizable monomer is a massive monomer selected from the group consisting of methacryloxypropyl tris (trimethylsiloxy) silane (TRIS), pentamethyldisiloxanyl methyl tris (trimethylsilyloxy) , phenyltretramethyl-disloxanylethyl acrylate, methyldi (trimethylsiloxy) methacryloxymethyl silane, 3- | tris (trimethylsilyloxy) silyl] propyl vinyl, 3 [tris (trimethylsiloxy) silyl] propyl allyl, and 3- [trisyl trimethylsyl (3-trisyl) triloxy] ) vinyl silylpropyl. [0179] 52. The monomer mixture of the preferred modality 50, wherein the massive monomer is present in about 0 to about 41.2 weight percent. [0180] 53. The monomer mixture of the preferred modality 50, wherein the massive monomer is present in about 34 to about 41 weight percent. [0181] 54. The monomer mixture of the preferred embodiment 50, wherein the massive monomer is present in about 25 to about 41 weight percent. [0182] 55. The monomer blend of preferred embodiment 51, wherein the massive monomer is present in about 0 to about 41.2 weight percent. [0183] 56. The monomer blend of preferred embodiment 51, wherein the massive monomer is present in about 34 to about 41 weight percent. [0184] 57. The monomer blend of preferred embodiment 51, wherein the massive monomer is present in about 25 to about 41 weight percent. Petition 870190055152, of 06/14/2019, p. 59/123 55/62 [0185] 58. The monomer mixture of the preferred embodiment 26, wherein the monomer mixture comprises a mixture containing at least one monomer containing silicone and at least one hydrophilic monomer. [0186] 59. The monomer blend of preferred embodiment 26, wherein the monomer blend comprises a separate crosslinker. [0187] 60. The monomer mixture of preferred mode 59, wherein the separate crosslinker is selected from the group consisting of methacrylates, ethylene glycol dimethacrylate (EGDMA) and allyl methacrylate (AMA). [0188] 61. The monomer blend of the preferred embodiment 60, wherein the separate crosslinker is present between about 0 to about 76 weight percent. [0189] 62. The monomer blend of preferred embodiment 60, wherein the separate crosslinker is present between about 2 to about 20 weight percent. [0190] 63. The monomer mixture of the preferred embodiment 60, wherein the separate crosslinker is present between about 5 to about 13 weight percent. [0191] 64. The monomer blend of preferred embodiment 27, wherein the silicone-containing monomer is a crosslinking agent. [0192] 65. The monomer blend of preferred embodiment 20, wherein the second copolymerizable monomer is a hydrophilic monomer. [0193] 66. The monomer blend of preferred mode 65, wherein the hydrophilic monomer is selected from the group consisting of unsaturated carboxylic acids, methacrylic acids, acrylic acids; substituted acrylic alcohols, 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate; vinyl lactams, N-vinylpyrrolidone (NVP), 1-vinylazonan-2-a; acylamides, methacrylamide, N, N-dimethylacylamide (DMA) and mixtures thereof. [0194] 67. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 60 weight percent. [0195] 68. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 20 to about 45 weight percent. Petition 870190055152, of 06/14/2019, p. 60/123 56/62 [0196] 69. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 48.6 percent by weight. [0197] 70. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 30 weight percent. [0198] 71. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 25 weight percent. [0199] 72. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 95 weight percent. [0200] 73. The monomer blend of preferred embodiment 65, wherein the hydrophilic monomer is present separately or in combined weight in amounts between about 2 to about 7 weight percent. [0201] 74. The monomer blend of preferred embodiment 21, wherein the second copolymerizable monomer is a hydrophilic monomer. [0202] 75. The monomer blend of preferred mode 74, wherein the hydrophilic monomer is selected from the group consisting of unsaturated carboxylic acids, methacrylic acids, acrylic acids; substituted acrylic alcohols, 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate; vinyl lactams, N-vinylpyrrolidone (NVP), 1-vinylazonan-2-a; acylamides, methacrylamide, N, N-dimethylacylamide (DMA) and mixtures thereof. [0203] 76. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 60 weight percent. [0204] 77. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 20 to about 45 weight percent. [0205] 78. The monomer mixture of the preferred modality 74, in which the Petition 870190055152, of 06/14/2019, p. 61/123 57/62 hydrophilic monomer is present separately or in combined weight in amounts between about 0 to about 48.6 percent by weight. [0206] 79. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 30 weight percent. [0207] 80. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 25 weight percent. [0208] 81. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 0 to about 9.5 weight percent. [0209] 82. The monomer blend of preferred embodiment 74, wherein the hydrophilic monomer is present separately or by combined weight in amounts between about 2 to about 7 weight percent. [0210] 83. The monomer blend of preferred embodiment 36, further comprising an organic diluent. [0211] 84. The monomer mixture of the preferred modality 83, in which the organic diluent is selected from the group consisting of alcohols, tert-butanol (TBA), tert-amyl alcohol, hexanol and nonanol; diols, ethylene glycol; polyols, glycerol and their mixtures. [0212] 85. The monomer blend of preferred embodiment 83, wherein the organic diluent is present in about 0 to about 60% by weight of the monomeric mixture. [0213] 86. The monomer mixture of the preferred embodiment 83, wherein the organic diluent is present in about 1 to about 40% by weight. [0214] 87. The monomer blend of preferred embodiment 83, wherein the organic diluent is present in about 2 to about 30% by weight. [0215] 88. The monomer blend of preferred embodiment 83, wherein the organic diluent is present in about 3 to about 25% by weight. [0216] 89. The monomer blend of preferred embodiment 40 additionally comprising an organic diluent. Petition 870190055152, of 06/14/2019, p. 62/123 58/62 [0217] 90. The monomer mixture of the preferred embodiment 89, in which the organic diluent is selected from the group consisting of alcohols, tert-butanol (TBA), tert-amyl alcohol, hexanol and nonanol; diols, ethylene glycol; polyols, glycerol and their mixtures. [0218] 91. The monomer blend of preferred embodiment 89, wherein the organic diluent is present in about 0 to about 60% by weight of the monomeric mixture. [0219] 92. The monomer blend of preferred embodiment 89, wherein the organic diluent is present in about 1 to about 40% by weight. [0220] 93. The monomer blend of preferred embodiment 89, wherein the organic diluent is present in about 2 to about 30% by weight. [0221] 94. The monomer blend of preferred embodiment 89, wherein the organic diluent is present in about 3 to about 25% by weight. [0222] 95. A hydrogel contact lens comprising a mixture of polymerized monomers comprising a mixture of polymerizable monomers comprising about 0.1 to about 75.8 weight percent of a methacrylamide crosslinker, about 0 to about 41.2 weight percent of a massive siloxane monomer, about 0 to about 78 weight percent of at least one hydrophilic monomer, about 0 to about 48.6 weight percent of an alcohol, about 0, 1 to about 29.9 weight percent of a polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group, about 0.1 to about 1.0 weight percent of an initiator and about 90 to about 200 parts per million a visibility coloring. [0223] 96. The hydrogel contact lens of preferred embodiment 95 comprising the polymerizable monomer blend parts comprising about 5 to about 13 weight percent of a methacrylamide crosslinker, about 34 to about 41 weight percent of a massive siloxane monomer, about 28 to about 52 weight percent of at least one hydrophilic monomer, about 0 to about 25 weight percent of an alcohol, about 5 to about 15 weight percent of an polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group, about 0.2 to about 0.8 weight percent of a Petition 870190055152, of 06/14/2019, p. 63/123 59/62 primer and about 90 to about 145 parts per million of a visibility color. [0224] 97. The preferred embodiment hydrogel contact lens 95 comprising the polymerizable monomer blend parts comprising about 2 to about 8 weight percent of a methacrylamide crosslinker, about 25 to about 38 weight percent of a massive siloxane monomer, about 35 to about 45 weight percent of at least one hydrophilic monomer, about 3 to about 8 weight percent of an alcohol, about 10 to about 13 weight percent of an polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group, about 0.3 to about 0.6 weight percent of an initiator and about 145 to about 200 parts per million of a visibility dye. [0225] 98. A mixture of monomers used to form a medical device, wherein the mixture of monomers comprises at least one monomer selected from the group consisting of any of the monomers of preferred modalities 1-17 and, when polymerized, form a medical ophthalmic device to be implanted in or over an eye. [0226] 99. A medical device comprising a mixture of polymerized monomers of any of the modalities 18-94. [0227] 100. The 99 medical device, wherein the medical device is coated with a polymer comprising at least one of the following monomers: HEMA, glyceryl methacrylate, methacrylic acid (MAA), acrylic acid (AA), methacrylamide, acylamide, N, N'-dimethylmetacylamide, or N, N'-dimethylacylamide; its copolymers; hydrophilic prepolymers, such as poly (alkylene oxide) are ethylenically unsaturated, cyclic lactams such as N-vinyl-2-pyrrolidone (NVP), vinyl carbonate monomers or vinyl carbamate. [0228] 101. A method of making a medical device comprising providing a mixture of monomers comprising at least one monomer selected from the group consisting of any of the monomers of preferred embodiments 1-17 in a mold suitable to form a medical device and expose the Petition 870190055152, of 06/14/2019, p. 64/123 60/62 mold containing the monomer mixture at least visible light at a sufficient intensity and for a sufficient period of time, in such a way that the monomer mixture is polymerized and forms a medical ophthalmic device to be implanted into or over an eye . [0229] 102. A hydrogel contact lens system comprising a mixture of polymerized monomers of any of the monomer mixtures of modalities 18-94 placed in a package comprising a flange with a well formed in it to hold a contact lens in solution, a flexible cover plate that extends over the flange and is sealed around the perimeter of the well to seal the lens and solution in the well where the package has at least one first and second support structures formed opposite each other and generally extending perpendicular to the flange on which the support structures are configured to stably support the packaging on a flat surface. [0230] 103. The hydrogel contact lens system of mode 102 further comprising as a component of the packaging system, a packaging solution comprising at least one component selected from the group consisting of anionic polymers such as poly (acrylic acid) , poly (acylamide-co-acrylic acid) or carboxymethylcellulose; cationic polymers such as JR polymer or polymers with latent amines; zwitterionic components such as phosphocholine, polyphosphocholine or latent amino acids; polypeptides such as poly (glutamic acid) or Poli (lysine); nonionic surfactants such as Tetronic Tl 107, Tetronic T908, hydroxypropyl methylcellulose, silicone surfactants (NVP-co-TRIS VC) or Glycereth cocoate and mixtures of any of the components of the previous packaging solution. [0231] 104. The hydrogel contact lens system of modalities 102 or 103 wherein each support structure includes a main wall and a secondary wall arranged in parallel planes generally spaced apart from each other. [0232] 105. The hydrogel contact lens system of modality 104 in which the main and secondary wall interconnect or touch along one or more Petition 870190055152, of 06/14/2019, p. 65/123 61/62 points of these. [0233] 106. The hydrogel contact lens system of any of the 102-105 modes in which the secondary wall is located internally in a respective main wall. [0234] 107. A polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group substantially in the manner shown and described herein. [0235] 108. A blend of monomers comprising a polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group and at least one other monomer substantially in the manner shown and described herein. [0236] 109. A medical device comprising a mixture of polymerized monomers comprising a polycarbosiloxane monomer containing monoethylenically unsaturated polymerizable group and at least one other monomer substantially in the manner shown and described herein. [0237] 110. The 109 medical device, wherein the medical device is coated with a coating material comprising at least one of the following materials: HEMA, glyceryl methacrylate, methacrylic acid (MAA), acrylic acid (AA), methacrylamide, acylamide, N, N'-dimethylmethacrylamide, or N, N'dimethylacylamide; its copolymers; hydrophilic prepolymers, such as poly (alkylene oxide) s ethylenically unsaturated (s), cyclic lactams such as N-vinyl-2-pyrrolidone (NVP), or derivatives thereof, hydrophilic vinyl carbonate or vinyl carbamate substantially as shown herein and described. [0238] 111. A hydrogel contact lens system comprising a mixture of polymerized monomers of any of the monomer mixtures of modalities 18-94 placed in a package comprising a flange with a well formed in it to hold a contact lens in solution, a flexible cover plate that extends over the flange and is sealed around the perimeter of the well to seal the lens and solution in the well where the package has at least one first and second support structures formed opposite each other and Petition 870190055152, of 06/14/2019, p. 66/123 62/62 generally extending perpendicularly to the flange where the support structures are configured to stably support the packaging on a flat surface where the solution is a packaging solution comprising at least one component selected from the group consisting of polymers anionics such as poly (acrylic acid), poly (acylamide-co-acrylic acid) or carboxymethylcellulose; cationic polymers such as JR polymer or polymers having latent amines; zwitterionic components such as phosphocholine, polyphosphocholine or latent amino acids; polypeptides such as poly (glutamic acid) or poly (lysine); nonionic surfactants such as Tetronic Tl 107, Tetronic T908, hydroxypropyl methylcellulose, silicone surfactants (NVP-co-TRIS VC) or Glycereth cocoate and mixtures of any of the components of the previous packaging solution substantially in the manner shown here and described. [0239] 112. A method of making a hydrogel contact lens comprising as a comonomer in a mixture of polymerized monomers, a polycarbossiloxane monomer containing monoethylenically unsaturated polymerizable group in which the method is carried out substantially in the manner shown and described herein. [0240] 113. A hydrogel contact lens system comprising as part of a packaging solution in the polyphosphorylcholine hydrogel contact lens system. [0241] It should be understood that several changes can be made to the modalities disclosed here. Therefore, the previous description should not be interpreted as limiting, but merely as exemplifications of the preferred modalities. For example, the functions described previously implemented as the best way to operate the present invention, are for the purpose of illustration only. Other arrangements and methods can be implemented by those skilled in the art without departing from the scope and spirit of this invention. Furthermore, those skilled in the art will notice other changes in the scope and spirit of the resources and advantages attached to it.
权利要求:
Claims (15) [1] 1. Hydrogel contact lens, characterized by the fact that it comprises a mixture of polymerized monomers comprising a mixture of polymerizable monomers comprising 0.1 to 75.8 percent by weight of a methacrylamide crosslinker, 0 to 41.2 percent by weight of 3 methacryloxypropyltris (trimethylsiloxy) silane (TRIS), 0 to 78 weight percent of at least one hydrophilic monomer being selected from 1-vinyl-2-pyrrolidone (NVP), N, N'-dimethylacrylamide (DMA) or methacrylate of 2-hydroxyethyl (HEMA) or a mixture thereof, 0 to 48.6 weight percent hexanol, 0.1 to 29.9 weight percent of a monoethylenically unsaturated polymerizable group containing polycarbonyl silane monomer, where the polycarbossiloxane monomer comprises at least one [silyl-alkyl siloxanyl] group, 0.1 to 1.0 weight percent of an initiator and 90 to 200 parts per million of a visibility dye. [2] 2. Hydrogel contact lens according to claim 1, characterized in that it comprises, as part of a polymerizable monomer, a mixture comprising 5 to 13 weight percent of a methacrylamide crosslinker, 34 to 41 weight percent 3 methacryloxypropyltris (trimethylsiloxy) silane (TRIS), 28 to 52 weight percent of at least one hydrophilic monomer being selected from 1-vinyl-2-pyrrolidone (NVP), N, N'-dimethylacrylamide (DMA) or 2-methacrylate -hydroxyethyl (HEMA) or a mixture thereof, 0 to 25 weight percent hexanol, 5 to 15 weight percent monoethylenically unsaturated polymerizable group containing polycarbonyl silane monomer, wherein the polycarbonyl silane monomer comprises at least one group- [silyl-alkyl siloxanil], 0.2 to 0.8 weight percent of an initiator and 90 to 145 parts per million of a visible color. [3] 3. Hydrogel contact lens according to claim 1, characterized in that it comprises, as part of a polymerizable monomer, a mixture comprising 2 to 8 weight percent of a methacrylamide crosslinker, 25 to 38 weight percent 3 methacryloxypropyltris (trimethylsiloxy) silane TRIS, 35 to 45 weight percent hair Petition 870190055152, of 06/14/2019, p. 68/123 2/6 minus a hydrophilic monomer being selected from 1-vinyl-2-pyrrolidone (NVP), Ν, Ν'-dimethylacrylamide (DMA) or 2-hydroxyethyl methacrylate (HEMA) or a mixture thereof, 3 to 8 percent by weight of a hexanol, 10 to 13 weight percent of a monoethylenically unsaturated polymerizable group containing polycarbosiloxane monomer, wherein the polycarbosiloxane monomer comprises at least one group- [silylalkyl siloxanyl], 0.3 to 0.6 percent by weight of an initiator and 145 to 200 parts per million of a visibility color. [4] 4. Hydrogel contact lens according to any one of claims 1-3, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbosiloxane monomer is a monomer with a structural formula (I): Rs n where X is the residue of a ring opening agent or a capping agent; L is the same or different and is a linking group or a bond; V is an ethylenically unsaturated polymerizable group; R1, R2, R3, R4, Rs, R6 are independently H, alkyl, halo alkyl, heteroalkyl, alkyl cycle, alkyl heterocycle, alkenyl, alkenyl halo, or aromatic; R7 and Rs when present are independently H or alkyl where at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100. [5] Hydrogel contact lens according to any one of claims 1-3, characterized in that the monoethylenically unsaturated polymerizable group containing polycarbonylsiloxane monomer is a monomer with a structural formula (H) Petition 870190055152, of 06/14/2019, p. 69/123 3/6 where L is the same or different and is a linking group or a bond and V is the same or different and is an ethylenically unsaturated polymerizable group, Ri, R2, R3, R4, Rs, R6 and R9 are independently H, alkyl, alkyl halo, alkyl cycle, alkyl heterocycle, alkenyl, alkenyl halo, or aromatic, R7 and Rs are independently H or alkyl where at least one of R7 or Rs is hydrogen, y is 2-7 and n is 1-100. [6] 6. Hydrogel contact lens according to claim 4, characterized by the fact that X is a residue of a ring opening agent selected from the group consisting of alkyl lithiums, alkoxides, trialkylsiloxylites and acrylic ester polysiloxane prepolymers capped in the presence of an acid catalyst. [7] 7. Hydrogel contact lens according to claim 4 or 5, characterized in that the linker group is selected from the group consisting of substituted or unsubstituted alkyl, alkyl ether, alkenyls, alkenyl ethers, haloalkyls, siloxanes substituted or unsubstituted, and monomers capable of propagating the ring opening. [8] Hydrogel contact lens according to any one of claims 1 -3, characterized by the fact that the monoethylenically polymerizable group containing unsaturated polycarbosiloxane monomer is a monomer with a structural formula (III): wherein R9, R10 and R11 are independently H, alkyl, haloalkyl or other substituted alkyl groups, n is 1 -100 and 1 is 0-10. [9] 9. Hydrogel contact lens, according to any of the Petition 870190055152, of 06/14/2019, p. 70/123 4/6 claims 1-3, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbosiloxane monomer is a monomer with a structural formula (IV): where n is 1 -100. [10] 10. Hydrogel contact lens according to claim 9, characterized by the fact that n is 2-80, or where n is 3-20, or where n is 5-15. [11] 11. Hydrogel contact lens according to claim 4 or 5, characterized by the fact that V is selected from the group consisting of acrylates, methacrylates, vinyl carbonates, O-vinyl carbamates, N-vinyl carbamates, acrylamides and methacrylamides. [12] 12. Hydrogel contact lens according to claim 4, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbonossiloxane monomer is a monomer with a structural formula selected from the group consisting of the following structural formulas: Petition 870190055152, of 06/14/2019, p. 71/123 5/6 (Vllj. IV), UX). [13] 13. Hydrogel contact lens according to claim 4, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbossiloxane monomer is a monomer with a structural formula selected from the group consisting of the following structural formulas: (X). [XI). (XII) Petition 870190055152, of 06/14/2019, p. 72/123 6/6 where R9, R10 and R11 are independently H, alkyl, haloalkyl or other substituted alkyl groups and n is 1-100 and 1 is 0-10. [14] 14. Hydrogel contact lens according to claim 4, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbossiloxane monomer is a monomer with a structural formula selected from the group consisting of the following structural formulas: X I .Si I (XIII). (XV) where n is 1 -100 and X- is a counterion to provide a total neutral charge. [15] 15. Hydrogel contact lens according to claim 4, characterized by the fact that the monoethylenically unsaturated polymerizable group containing polycarbonylsiloxane monomer is a monomer with the following structural formula:
类似技术:
公开号 | 公开日 | 专利标题 BR112012000503B1|2019-08-20|HYDROGEL CONTACT LENS US8827447B2|2014-09-09|Mono ethylenically unsaturated polymerizable group containing polycarbosiloxane monomers US9039174B2|2015-05-26|Ethylenically unsaturated polymerizable groups comprising polycarbosiloxane monomers ES2390246T3|2012-11-08|Process for manufacturing cationic hydrophilic siloxanyl monomers WO2014143926A1|2014-09-18|Ethylenically unsaturated polymerizable groups comprising polycarbosiloxane monomers JP5842297B2|2016-01-13|Silicone hydrogel contact lenses with acceptable levels of energy loss JP5904603B2|2016-04-13|Dimensionally stable silicone hydrogel contact lens US7994356B2|2011-08-09|Mono ethylenically unsaturated polycarbosiloxane monomers CN101102749B|2011-10-05|Ophthalmic compositions comprising polyether substituted polymers ES2389567T3|2012-10-29|Monomers containing silicon terminally protected with polymerizable cationic hydrophilic groups ES2355773T3|2011-03-30|SURFACE TREATMENT OF MEDICAL DEVICES. ES2372010T3|2012-01-12|PACKING SOLUTIONS. JP5970482B2|2016-08-17|Silicone hydrogel contact lens CN101326450A|2008-12-17|Method of packaging a lens WO2009076032A1|2009-06-18|Method for treating ophthalmic lenses WO2009076029A1|2009-06-18|Method for treating ophthalmic lenses ES2641495T3|2017-11-10|Mixture of hydrogel monomers containing added water ES2366968T3|2011-10-27|PROCESS FOR MANUFACTURING MONOMERS OF SILOXANIL CATIÓNIC HYDROPHILES.
同族专利:
公开号 | 公开日 HK1165012A1|2012-09-28| WO2011005937A3|2011-05-12| EP2452212B1|2015-03-25| KR20120044356A|2012-05-07| JP5800369B2|2015-10-28| US20110009519A1|2011-01-13| SG176987A1|2012-01-30| CA2767171A1|2011-01-13| US8420711B2|2013-04-16| WO2011005937A2|2011-01-13| HUE024972T2|2016-01-28| JP2012533090A|2012-12-20| EP2452212A2|2012-05-16| CN102483467B|2014-01-08| BR112012000503A2|2017-04-04| CA2767171C|2014-04-29| CN102483467A|2012-05-30| KR101738186B1|2017-05-19| PL2452212T3|2015-08-31| ES2537828T3|2015-06-12|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 US3808179A|1972-06-16|1974-04-30|Polycon Laboratories|Oxygen-permeable contact lens composition,methods and article of manufacture| US4208506A|1977-07-25|1980-06-17|Bausch & Lomb Incorporated|Polyparaffinsiloxane shaped article for use in biomedical applications| JPS6410808B2|1983-04-06|1989-02-22|Toyo Kontakutorenzu Kk| US4686267A|1985-10-11|1987-08-11|Polymer Technology Corporation|Fluorine containing polymeric compositions useful in contact lenses| US4910277A|1988-02-09|1990-03-20|Bambury Ronald E|Hydrophilic oxygen permeable polymers| US5070215A|1989-05-02|1991-12-03|Bausch & Lomb Incorporated|Novel vinyl carbonate and vinyl carbamate contact lens material monomers| US5034461A|1989-06-07|1991-07-23|Bausch & Lomb Incorporated|Novel prepolymers useful in biomedical devices| US5358995A|1992-05-15|1994-10-25|Bausch & Lomb Incorporated|Surface wettable silicone hydrogels| US5321108A|1993-02-12|1994-06-14|Bausch & Lomb Incorporated|Fluorosilicone hydrogels| US5374662A|1993-03-15|1994-12-20|Bausch & Lomb Incorporated|Fumarate and fumaramide siloxane hydrogel compositions| US5451651A|1993-12-17|1995-09-19|Bausch & Lomb Incorporated|Urea and urethane monomers for contact lens materials| US5710302A|1995-12-07|1998-01-20|Bausch & Lomb Incorporated|Monomeric units useful for reducing the modules of silicone hydrogels| JP2000502329A|1995-12-07|2000-02-29|ボシュアンドロムインコーポレイテッド|Monomer units useful for reducing the modulus of low water content polymeric silicone compositions| GB9711818D0|1997-06-06|1997-08-06|Bausch & Lomb|Contact lens packing solutions and methods for improving the comfort of disposable contact lenses| US5831110A|1997-10-23|1998-11-03|Chisso Corporation|Fluorine-containing siloxane compound and process for production thereof| US6943203B2|1998-03-02|2005-09-13|Johnson & Johnson Vision Care, Inc.|Soft contact lenses| US5998498A|1998-03-02|1999-12-07|Johnson & Johnson Vision Products, Inc.|Soft contact lenses| US6367929B1|1998-03-02|2002-04-09|Johnson & Johnson Vision Care, Inc.|Hydrogel with internal wetting agent| JP4281853B2|1998-10-28|2009-06-17|東レ・ダウコーニング株式会社|Ophthalmic lens material| JP2003505728A|1999-07-27|2003-02-12|ボシュ・アンド・ロム・インコーポレイテッド|Contact lens material| KR100697176B1|1999-08-20|2007-03-20|바이엘 악티엔게젤샤프트|Inorganic Coating Composition, a Method for Producing Same and the Use Thereof| US6384172B1|2001-01-02|2002-05-07|Michigan Molecular Institute|Hyperbranched polycarbosilanes, polycarbosiloxanes, polycarbosilazenes and copolymers thereof| US6891010B2|2001-10-29|2005-05-10|Bausch & Lomb Incorporated|Silicone hydrogels based on vinyl carbonate endcapped fluorinated side chain polysiloxanes| JP4782508B2|2004-09-30|2011-09-28|株式会社シード|High oxygen permeation hydrous ophthalmic lens| US20100280147A1|2008-02-15|2010-11-04|Laura Hartmann|High refractive index interpenetrating networks for ophthalmic applications| WO2007017243A1|2005-08-10|2007-02-15|Novartis Ag|Silicone hydrogels| EP1969397B1|2005-12-14|2017-11-08|Novartis AG|Method for preparing silicone hydrogels| US7960447B2|2006-04-13|2011-06-14|Bausch & Lomb Incorporated|Cationic end-capped siloxane prepolymer for reduced cross-link density| US7951897B2|2007-01-26|2011-05-31|Bausch & Lomb Incorporated|Synthesis of cationic siloxane prepolymers| US7901073B2|2007-07-10|2011-03-08|Bausch & Lomb Incorporated|Silicone hydrogel with composite hydrophilic and silicone polymers prepared with selective crosslink agents| US20090168013A1|2007-12-27|2009-07-02|Kunzler Jay F|Trimethylsilyl-Capped Polysiloxane Macromonomers Containing Polar Fluorinated Side-Chains| US7915323B2|2009-07-09|2011-03-29|Bausch & Lamb Incorporated|Mono ethylenically unsaturated polycarbosiloxane monomers|WO2014143926A1|2013-03-15|2014-09-18|Bausch & Lomb Incorporated|Ethylenically unsaturated polymerizable groups comprising polycarbosiloxane monomers| US8827447B2|2009-07-09|2014-09-09|Bausch & Lomb Incorporated|Mono ethylenically unsaturated polymerizable group containing polycarbosiloxane monomers| US9039174B2|2009-07-09|2015-05-26|Bausch & Lomb Incorporated|Ethylenically unsaturated polymerizable groups comprising polycarbosiloxane monomers| WO2011116206A1|2010-03-18|2011-09-22|Johnson & Johnson Vision Care, Inc.|Silicone acrylamide monomer, polymer, ophthalmic lens, and contact lens| JP5720103B2|2010-03-18|2015-05-20|東レ株式会社|Silicone hydrogels, ophthalmic lenses and contact lenses| KR102057814B1|2010-07-30|2019-12-19|노파르티스 아게|A silicone hydrogel lens with a crosslinked hydrophilic coating| CN103476779B|2011-02-01|2016-04-06|帝斯曼知识产权资产管理有限公司|There is the monomer containing silicone of end group hydrophilic| AU2011363044A1|2011-03-21|2013-09-26|Momentive Performance Materials Inc.|Siloxane monomers containing hydrolysis resistance carbosiloxane linkage, process for their preparation and thin films containing the same for contact lens application| US10391179B2|2011-03-21|2019-08-27|Momentive Performance Materials Inc.|Organomodified carbosiloxane monomers containing compositions and uses thereof| EP2688938B1|2011-03-21|2019-10-16|Momentive Performance Materials Inc.|Organomodified carbosiloxane monomers containing compositions and uses thereof| WO2013055746A1|2011-10-12|2013-04-18|Novartis Ag|Method for making uv-absorbing ophthalmic lenses by coating| US8937111B2|2011-12-23|2015-01-20|Johnson & Johnson Vision Care, Inc.|Silicone hydrogels comprising desirable water content and oxygen permeability| SG11201504763UA|2012-12-17|2015-07-30|Novartis Ag|Method for making improved uv-absorbing ophthalmic lenses| EP2951242B1|2013-01-31|2019-09-11|Momentive Performance Materials Inc.|Water soluble silicone material| KR20160010428A|2013-03-21|2016-01-27|시파메드 홀딩스, 엘엘씨|Accommodating intraocular lens| US9486311B2|2013-02-14|2016-11-08|Shifamed Holdings, Llc|Hydrophilic AIOL with bonding| US10195018B2|2013-03-21|2019-02-05|Shifamed Holdings, Llc|Accommodating intraocular lens| HUE038809T2|2013-12-17|2018-11-28|Novartis Ag|A silicone hydrogel lens with a crosslinked hydrophilic coating| AU2015201371A1|2014-03-31|2015-10-15|Johnson & Johnson Vision Care, Inc.|Silicone acrylamide copolymer| AU2015201321A1|2014-03-31|2015-10-15|Johnson & Johnson Vision Care, Inc.|Silicone acrylamide copolymer| WO2015164630A1|2014-04-25|2015-10-29|Novartis Ag|Carbosiloxane vinylic monomers| JP6378359B2|2014-04-25|2018-08-22|ノバルティス アーゲー|Hydrophilized carbosiloxane vinyl monomer| US20150366311A1|2014-06-19|2015-12-24|Coopervision International Holding Company, Lp|Protection of Contact Lenses from Microbial Contamination Caused by Handling| CN110279494A|2014-08-26|2019-09-27|施菲姆德控股有限责任公司|Modulability intraocular lens| HUE046948T2|2014-08-26|2020-03-30|Novartis Ag|Method for applying stable coating on silicone hydrogel contact lenses| TWI541291B|2015-06-18|2016-07-11|明基材料股份有限公司|Material for contact lenses, method for manufacturing contact lenses and contact lenses obtained thereby| JP6592189B2|2015-09-04|2019-10-16|ノバルティス アーゲー|Method for manufacturing a contact lens having a durable lubricious coating thereon| JP6680870B2|2015-09-04|2020-04-15|アルコン インク．|Soft silicone medical device with a durable lubricious coating thereon| US11141263B2|2015-11-18|2021-10-12|Shifamed Holdings, Llc|Multi-piece accommodating intraocular lens| EP3391100B1|2015-12-15|2020-08-12|Alcon Inc.|Amphiphilic branched polydiorganosiloxane macromers| US10227435B2|2015-12-15|2019-03-12|Novartis Ag|Polymerizable polysiloxanes with hydrophilic substituents| EP3391101B1|2015-12-15|2020-07-08|Alcon Inc.|Method for applying stable coating on silicone hydrogel contact lenses| SG11201803724TA|2015-12-15|2018-06-28|Novartis Ag|Method for producing contact lenses with a lubricious surface| BR112018011867A2|2015-12-15|2018-11-27|Novartis Ag|hydrophilized polycarbonosiloxanes vinyl cross-linking agents and uses thereof| JP6606294B2|2016-02-22|2019-11-13|ノバルティスアーゲー|Soft silicone medical device| EP3419961B1|2016-02-22|2020-09-02|Alcon Inc.|Uv/visible-absorbing vinylic monomers and uses thereof| CA3116257A1|2016-02-22|2017-08-31|Alcon Inc.|Uv-absorbing vinylic monomers and uses thereof| US11021558B2|2016-08-05|2021-06-01|Johnson & Johnson Vision Care, Inc.|Polymer compositions containing grafted polymeric networks and processes for their preparation and use| EP3516431B1|2016-09-20|2021-03-03|Alcon Inc.|Process for producing contact lenses with durable lubricious coatings thereon| US10676575B2|2016-10-06|2020-06-09|Johnson & Johnson Vision Care, Inc.|Tri-block prepolymers and their use in silicone hydrogels| JP6839295B2|2016-10-11|2021-03-03|アルコン インク．|Polymerizable Polydimethylsiloxane-Polyoxyalkylene Block Copolymer| US10301451B2|2016-10-11|2019-05-28|Novartis Ag|Chain-extended polydimethylsiloxane vinylic crosslinkers and uses thereof| CA3035490C|2016-10-26|2021-09-14|Novartis Ag|Amphiphilic branched polydiorganosiloxane macromers| US10350056B2|2016-12-23|2019-07-16|Shifamed Holdings, Llc|Multi-piece accommodating intraocular lenses and methods for making and using same| TW201827854A|2017-01-20|2018-08-01|鴻海精密工業股份有限公司|Eye lens material and eye lens using the same| CN110996848A|2017-05-30|2020-04-10|施菲姆德控股有限责任公司|Surface treatment of accommodating intraocular lenses and related methods and devices| EP3634309A4|2017-06-07|2020-12-16|Shifamed Holdings, LLC|Adjustable optical power intraocular lenses| HUE055667T2|2017-06-07|2021-12-28|Alcon Inc|Method for producing silicone hydrogel contact lenses| WO2018224975A1|2017-06-07|2018-12-13|Novartis Ag|Silicone hydrogel contact lenses| EP3928967A4|2017-06-07|2021-12-29|Alcon Inc|Silicone hydrogel contact lenses| US10752720B2|2017-06-26|2020-08-25|Johnson & Johnson Vision Care, Inc.|Polymerizable blockers of high energy light| US10723732B2|2017-06-30|2020-07-28|Johnson & Johnson Vision Care, Inc.|Hydroxyphenyl phenanthrolines as polymerizable blockers of high energy light| US10526296B2|2017-06-30|2020-01-07|Johnson & Johnson Vision Care, Inc.|Hydroxyphenyl naphthotriazoles as polymerizable blockers of high energy light| US10809181B2|2017-08-24|2020-10-20|Alcon Inc.|Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens| EP3676082A1|2017-08-29|2020-07-08|Alcon Inc.|Cast-molding process for producing contact lenses| AU2018381954A1|2017-12-13|2020-05-14|Alcon Inc.|Weekly and monthly disposable water gradient contact lenses| WO2019142132A1|2018-01-22|2019-07-25|Novartis Ag|Cast-molding process for producing uv-absorbing contact lenses| US10961341B2|2018-01-30|2021-03-30|Johnson & Johnson Vision Care, Inc.|Ophthalmic devices derived from grafted polymeric networks and processes for their preparation and use| US11034789B2|2018-01-30|2021-06-15|Johnson & Johnson Vision Care, Inc.|Ophthalmic devices containing localized grafted networks and processes for their preparation and use| WO2019162881A1|2018-02-26|2019-08-29|Novartis Ag|Silicone hydrogel contact lenses| US10935695B2|2018-03-02|2021-03-02|Johnson & Johnson Vision Care, Inc.|Polymerizable absorbers of UV and high energy visible light| US10996491B2|2018-03-23|2021-05-04|Johnson & Johnson Vision Care, Inc.|Ink composition for cosmetic contact lenses| WO2019186426A1|2018-03-28|2019-10-03|Alcon Inc.|Method for making silicone hydrogel contact lenses| EP3794388A1|2018-05-15|2021-03-24|Bausch & Lomb Incorporated|Water extractable ophthalmic devices| US11046636B2|2018-06-29|2021-06-29|Johnson & Johnson Vision Care, Inc.|Polymerizable absorbers of UV and high energy visible light| JP2021529353A|2018-07-03|2021-10-28|ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ|Water extractable ophthalmic device| US20200095187A1|2018-09-26|2020-03-26|Johnson & Johnson Vision Care, Inc.|Polymerizable absorbers of uv and high energy visible light| SG11202104402PA|2018-12-03|2021-06-29|Alcon Inc|Method for coated silicone hydrogel contact lenses| SG11202104403VA|2018-12-03|2021-06-29|Alcon Inc|Method for making coated silicone hydrogel contact lenses| WO2020159915A1|2019-01-29|2020-08-06|Bausch & Lomb Incorporated|Packaging solutions for contact lenses| SG11202108875UA|2019-04-10|2021-10-28|Alcon Inc|Method for producing coated contact lenses| EP3962961A1|2019-04-29|2022-03-09|Bausch & Lomb Incorporated|Glycophospholipid polymeric network and use thereof| US20200399429A1|2019-06-24|2020-12-24|Johnson & Johnson Vision Care, Inc.|Silicone hydrogel contact lenses having non-uniform morphology| US20200407337A1|2019-06-28|2020-12-31|Johnson & Johnson Vision Care, Inc.|Photostable mimics of macular pigment| US20200407324A1|2019-06-28|2020-12-31|Johnson & Johnson Vision Care, Inc.|Polymerizable fused tricyclic compounds as absorbers of uv and visible light| US20210003754A1|2019-07-02|2021-01-07|Johnson & Johnson Vision Care, Inc.|Core-shell particles and methods of making and using thereof| US20210061934A1|2019-08-30|2021-03-04|Johnson & Johnson Vision Care, Inc.|Contact lens displaying improved vision attributes| US20210063770A1|2019-08-30|2021-03-04|Johnson & Johnson Vision Care, Inc.|Multifocal contact lens displaying improved vision attributes| US20210190992A1|2019-12-19|2021-06-24|Johnson & Johnson Vision Care, Inc.|Contact lens containing photosensitive chromophore and package therefor| US20210301088A1|2020-03-18|2021-09-30|Johnson & Johnson Vision Care, Inc.|Ophthalmic devices containing transition metal complexes as high energy visible light filters| US20210291469A1|2020-03-19|2021-09-23|Alcon Inc.|Method for producing embedded or hybrid hydrogel contact lenses| US20210389731A1|2020-06-15|2021-12-16|Johnson & Johnson Vision Care, Inc.|Systems and methods for indicating the time elapsed since the occurrence of a triggering event| US20210388142A1|2020-06-16|2021-12-16|Johnson & Johnson Vision Care, Inc.|Amino acid-based polymerizable compounds and ophthalmic devices prepared therefrom| US20210388141A1|2020-06-16|2021-12-16|Johnson & Johnson Vision Care, Inc.|Imidazolium zwitterion polymerizable compounds and ophthalmic devices incorporating them|
法律状态:
2019-01-15| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2019-04-16| B06T| Formal requirements before examination [chapter 6.20 patent gazette]| 2019-08-06| B09A| Decision: intention to grant [chapter 9.1 patent gazette]| 2019-08-20| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2010, OBSERVADAS AS CONDICOES LEGAIS |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US12/499854|2009-07-09| US12/499,854|US7994356B2|2009-07-09|2009-07-09|Mono ethylenically unsaturated polycarbosiloxane monomers| PCT/US2010/041336|WO2011005937A2|2009-07-09|2010-07-08|Mono ethylenically unsaturated polymerizable group containing polycarbosiloxane monomers| US12/832,174|US8420711B2|2009-07-09|2010-07-08|Mono ethylenically unsaturated polymerizable group containing polycarbosiloxane monomers| US12/832174|2010-07-08| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|